Antibody conjugate comprising urea derivative compound having neosubstrate-degrading activity, and pharmaceutical composition comprising same
An antibody conjugate with a urea derivative compound addresses the limitations of conventional cancer treatments by selectively degrading neosubstrates in tumor cells, enhancing treatment efficacy and overcoming resistance.
Patent Information
- Application Number
- PCT/KR2026/005694
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-12-12
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-19
AI Technical Summary
Existing drug discovery methods struggle to target proteins lacking clear binding pockets, such as nuclear transcription factors and protein aggregates, limiting the development of effective cancer treatments, and conventional antibody-drug conjugates face issues with therapeutic index, resistance, and limited efficacy.
Development of an antibody conjugate using a urea derivative compound as a neosubstrate degrader, combined with a CD33 antigen-specific binding antibody and a cleavable linker, to selectively deliver molecular adhesives to tumor cells, inducing target protein degradation through the ubiquitin-proteasome system.
Enhances cancer treatment efficacy by selectively degrading neosubstrates, overcoming resistance and achieving targeted protein degradation, even at low doses, with improved binding affinity and cancer cell killing effects.
Smart Images

Figure KR2026005694_19112026_PF_FP_ABST
Abstract
Description
Antibody conjugate comprising a urea derivative compound having neosubstrate degradation activity and a pharmaceutical composition comprising the same
[0001] The present invention relates to an antibody conjugate comprising a urea derivative compound having neosubstrate degradation activity and a pharmaceutical composition comprising the same. More specifically, the invention relates to an antibody conjugate comprising a urea derivative compound having neosubstrate degradation activity that can be usefully employed for the prevention or treatment of cancer by degrading neosubstrates, and a pharmaceutical composition comprising the same.
[0002] Most existing drug discovery is based on a method of directly regulating protein activity by binding drugs to specific active sites of disease-associated proteins that possess binding pockets, such as enzymes or receptor proteins. Consequently, proteins lacking clear binding pockets, such as nuclear transcription factors, scaffold proteins, and protein aggregates, remain undruggable targets for drug development. According to the Human Protein Atlas, FDA-approved drugs exist for only about 15% of the approximately 4,500 known disease-associated proteins.
[0003] As such, small molecule inhibitor-based approaches have inherent limitations in directly inhibiting target protein function because they can only be applied to proteins containing binding pockets. To overcome these limitations, targeted protein degradation (TPD) technology is gaining attention for its approach of eliminating pathogenic proteins themselves by utilizing intracellular protein degradation mechanisms, rather than blocking the activity of target proteins. TPD achieves therapeutic effects by inducing polyubiquitination of specific proteins using the ubiquitin-proteasome system, followed by selective degradation by proteasomes. In this process, E3 ubiquitin ligase plays a key role in recognizing substrate proteins and conferring ubiquitin tags.
[0004] In particular, it is known that some small molecules (molecular glues) alter or expand the substrate specificity of E3 ligases, causing proteins that were not originally degraded to be recognized as new substrates (neosubstrates). For example, the IMiD family (thalidomide, lenalidomide, pomalidomide) binds to cereblon, converts specific pathogenic proteins into neosubstrates, and induces their degradation.
[0005] Meanwhile, antibody-drug conjugates (ADCs) are being actively developed in the field of anticancer drugs as a technology that selectively delivers drugs to specific tissues by combining the target specificity of antibodies with the pharmacological activity of small molecule compounds. Conventional ADC payloads have primarily consisted of highly cytotoxic compounds such as microtubule inhibitors, DNA-damaging agents, or topoisomerase inhibitors. However, these payloads have problems such as a narrow therapeutic index, a high potential for resistance development, and limited efficacy in cases of target protein mutations or absence.
[0006] Accordingly, recently, approaches utilizing TPD-based molecular adhesives capable of selectively removing target proteins as ADC payloads, moving beyond cytotoxicity-based payloads, have been gaining attention. Molecular adhesive-based target protein degradation technology can achieve protein degradation even for non-target proteins that conventional small molecule inhibitors cannot bind to, by inducing interactions between E3 ubiquitin ligases and target proteins. Furthermore, since this method does not directly inhibit the active site, it can bypass the development of resistance caused by mutations in the active site, and cell-type specific protein degradation is possible by delivering the molecular adhesive only to cells expressing specific antigens. In addition, since target protein degradation can exhibit a catalytic modality, excellent efficacy can be demonstrated even at relatively low doses.
[0007] However, due to their structural characteristics, molecular adhesives are relatively lipophilic and may induce off-target degradation upon systemic administration. Therefore, platform technology capable of selectively delivering such molecular adhesives to target tissues is required. This invention relates to a molecular adhesive-based ADC that selectively delivers molecular adhesives to tumor cells using a target antibody. By combining the targeted delivery capability of the ADC with the target protein degradation ability of the molecular adhesive, this invention aims to overcome the therapeutic limitations of existing cytotoxicity-based ADCs and provide a novel mechanism of action.
[0008] To solve the aforementioned problem, the present invention aims to provide an antibody conjugate comprising a urea derivative compound having neosubstrate degradation activity that can be usefully used for the prevention or treatment of cancer by degrading the neosubstrate, and a pharmaceutical composition comprising the same.
[0009] To solve the above problem, a compound selected from a conjugate of a urea derivative compound represented by the following chemical formula 1 and a stereoisomer thereof is provided.
[0010] [Chemical Formula 1]
[0011]
[0012] In the above Chemical Formula 1, a is an integer from 1 to 8; Ab is a CD33 antigen-specific binding antibody; L is a cleavable linker; and P is a payload having the characteristics of a neosubstrate degrader represented by the following Chemical Formula 2;
[0013] [Chemical Formula 2]
[0014]
[0015] In the above chemical formula 2, the above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 Each is independently hydrogen, an alkyl group, an aminoalkyl carbonyl group, an alkylaminoalkyl carbonyl group, a heterocycloalkyl carbonyl group, an aminoalkyl group, an alkylaminoalkyl group, a hydroxyalkyl carbonyl group, a cycloalkyl group, a halocycloalkyl group, a heterocycloalkyl group, a heterobicycloalkyl group, a cycloalkyl-alkyl group, a heterocycloalkyl-alkyl group, a hydroxycarbonylalkyl group, an alkylhydroxycarbonylalkyl group, an aminecarbonylalkyl group, or an alkylaminecarbonylalkyl group; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above alkyl group, cycloalkyl group, and heterocycloalkyl group of are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above A 2is an alkyl group, an alkoxyalkyl group, an alkylaminocarbonylalkyl group, an alkylcarbonylaminoalkyl group, a carbonylalkyl group, an alkylaminoalkyl-alkyl group, an alcoholcy-alkoxyalkyl group, an alkylalkoxy-alkoxy group, or an alkylaminoalkyloxyalkyl group; and the above A 2 The above alkyl group and alkoxy group are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, an alkyl group, a hydroxyl group, an alkoxy group, an amine group, an alkylamine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or an alkyl group; X is NH, C(=O), O, or CF2; and Y is O, S, and NH.
[0016] In one embodiment, the slicable linker may have a structure of the following chemical formula 3, 4, or 5.
[0017] [Chemical Formula 3]
[0018]
[0019] [Chemical Formula 4]
[0020]
[0021] [Chemical Formula 5]
[0022]
[0023] In the above chemical formulas 3, 4, and 5, represents the binding site with Ab; represents a binding site with a neo-substrate decomposer; W is -C(=O)-, -C(=O)NR'-, -NR'-, or -N(C=O)R', where R' is hydrogen, C 1-4Alkylamino, -(CH2)nO(CH2)nNH2, -NH(CH2)2OC(O)NHSO2NH(CH2)2-, -NH(CH2)2OC(O)NHSO2NH(CH2)O(CH2)n- and; n is an integer from 1 to 10 and; Z 1 , Z 2 , Z 3 and Z 4 are either independently non-existent or are naturally occurring amino acid residues in the L- or D-set, and only Z 1 , Z 2 , Z 3 and Z 4 At least two of them are amino acid residues; R 14 is either non-existent, C1~C3 alkoxy or -Ar-CH2OH-, and P is either non-existent or -(maleimide-N)- that binds to Ab.
[0024] In one embodiment, the Z 1 , Z 2 , Z 3 and Z 4 is not present independently or is selected from the group consisting of L-valine, D-valine, L-citrulline, D-citrulline, L-alanine, D-alanine, L-glutamine, L-glutamic acid, D-glutamic acid, D-glutamine, L-aspartic acid, D-aspartic acid, L-asparagine, D-asparagine, L-phenylalanine, D-phenylalanine, L-lysine, D-lysine, and glycine; provided, however, that Z 1 , Z 2 , Z 3 and Z 4 At least two of them may be amino acid residues.
[0025] In one embodiment,
[0026] The above chemical formula 4 may have the structure of the following chemical formula 6.
[0027] [Chemical Formula 6]
[0028]
[0029] In the above chemical formula 6, R14 is absent, C1~C3 alkoxy or -Ar-CH2OH-, and D is absent or -(maleimide-N)- bonded to Ab.
[0030] In one embodiment, the above D may have the structure of the following chemical formula 7 or 8.
[0031] [Chemical Formula 7]
[0032]
[0033] [Chemical Formula 8]
[0034]
[0035] In the above chemical formulas 7 and 8, m is an integer from 1 to 4; represents the binding site with Ab; * represents the binding site with W or an amino group.
[0036] In one embodiment, the W may have the structure of the following chemical formula 9 or 10.
[0037] [Chemical Formula 9]
[0038]
[0039] [Chemical Formula 10]
[0040]
[0041] In the above chemical formulas 9 and 10, * indicates a bonding point with D; R15 is bonded to a phenyl group, R15 is -NH- or -(OCH2CH2)nNH-; and n is an integer from 2 to 6.
[0042] In one embodiment, the R 14 It may have the structure of the following chemical formula 11 or 12.
[0043] [Chemical Formula 11]
[0044]
[0045] [Chemical Formula 12]
[0046]
[0047] In the above chemical formulas 11 and 12, represents the binding site with the amino group; * represents the binding site with P.
[0048] In one embodiment, the A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently hydrogen, (C1-C5 alkyl) group, H2N-(C1-C5 alkyl)-C(=O)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-C(=O)-, (C3-C8 heterocycloalkyl)-C(=O)-, H2N-(C1-C5 alkyl)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-, HO-(C1-C5 alkyl)-C(=O)-, (C3-C8 cycloalkyl) group, (C3-C8 heterocycloalkyl) group, (C7-C 11 Heterobicycloalkyl) group, (C3-C8 cycloalkyl)-(C1-C5 alkyl)-, (C3-C8 heterocycloalkyl)-(C1-C5 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)-; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13The above (C1-C5 alkyl) group, (C3-C8 cycloalkyl) group and (C3-C8 heterocycloalkyl) group are substituted or unsubstituted with one or more selected from the group consisting of halogens and C1-C5 alkyls; and the above A 2 is -(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)HN-C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-C(=O)-NH(C1-C5alkyl)-, -C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-N(C1-C5alkyl)-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O- or -(C1-C5alkyl)HN-(C1-C5alkyl)-O-(C1-C5alkyl)-; and above A 2 The above (C1-C5 alkyl) and (C1-C5 alkyl)-O are each independently substituted or unsubstituted with one or more selected from the group consisting of halogens and (C1-C5 alkyl); and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, a (C1-C5 alkyl) group, a hydroxyl group, an alkoxy group, an amine group, a (C1-C5 alkyl)amine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or a (C1-C5 alkyl) group; and R 6 is hydrogen, deuterium, or a (C1-C5 alkyl) group; and the X 1 is NH, C(=O), O, or CF2; and the above X 2 is O, S, or NH; and the above Y may be CH2.
[0049] In one embodiment, the formula 2 is formula 2a or 2b;
[0050] [Chemical Formula 2a]
[0051]
[0052] [Chemical Formula 2b]
[0053]
[0054] In the above chemical formulas 2a and 2b, the above 76 , R 7 , R 8 and R 9 Each is independently hydrogen, (C1-C3 alkyl) group, H2N-(C1-C3 alkyl)-C(=O)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-C(=O)-, (C3-C6 heterocycloalkyl)-C(=O)-, H2N-(C1-C3 alkyl)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-, HO-(C1-C3 alkyl)-C(=O)-, (C3-C6 cycloalkyl) group, (C3-C6 heterocycloalkyl) group, (C7-C9 heterobicycloalkyl) group, (C3-C6 cycloalkyl)-(C1-C3 alkyl)-, (C3-C6 heterocycloalkyl)-(C1-C3 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, It may be (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)-.
[0055] In one embodiment, the (C1-C3 alkyl) group, the (C3-C6 cycloalkyl) group, or the (C3-C6 heterocycloalkyl) group may be substituted or unsubstituted with one or more selected from the group consisting of F, Cl, and (C1-C3 alkyl).
[0056] In one embodiment, the A 2It may be -(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)HN-C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-C(=O)-NH(C1-C3alkyl)-, -C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-N(C1-C3alkyl)-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O- or -(C1-C3alkyl)HN-(C1-C3alkyl)-O-(C1-C3alkyl)-.
[0057] In one embodiment, the (C1-C3alkyl) and (C1-C3alkyl)-O may each be independently substituted or unsubstituted with one or more types selected from the group consisting of F, Cl, and (C1-C3alkyl).
[0058] In one embodiment, the R 1 , R 2 , R 4 and R 5 Each can independently be hydrogen, F, Cl, Br, (C1-C5 alkyl) group, hydroxyl group, alkoxy group, or trifluoromethyl group.
[0059] In one embodiment, the R 3 It can be hydrogen, methyl group, ethyl group, propyl group, or iso-propyl group.
[0060] In one embodiment, the R 6 It can be hydrogen, deuterium, or a methyl group.
[0061] In one embodiment, X may be NH, C(=O) or CF2.
[0062] In one embodiment, the Y may be O or S.
[0063] The conjugate of a urea derivative compound according to the present invention can be usefully used for the prevention, alleviation, or treatment of cancer by degrading the neo-substrate.
[0064] The conjugate of the urea derivative compound according to the present invention can improve the neosubstrate degradation rate and maximum degradation capacity by specifically introducing -NO-, -ON-, or -NN- type functional groups at the structural ends, thereby influencing the binding affinity between cereblon and the target protein, and consequently, the cancer cell killing effect can also be enhanced. Furthermore, due to its structural characteristics, it can be used as an antibody conjugate drug.
[0065] Figure 1 shows the relative strength of GSPT1 according to one embodiment of the present invention.
[0066] Figure 2 shows the results of an in vivo activity experiment on HL-60 of a urea derivative compound conjugate having neo-substrate degradation activity according to one embodiment of the present invention.
[0067] Figure 3 shows the results of an in vivo activity experiment on MV4-11 of a urea derivative compound conjugate having neo-substrate degradation activity according to one embodiment of the present invention.
[0068] Preferred embodiments of the present invention are described in detail below. In describing the present invention, detailed descriptions of related prior art are omitted if it is determined that such detailed descriptions may obscure the essence of the invention. Throughout the specification, singular expressions should be understood to include plural expressions unless the context clearly indicates otherwise, and terms such as "include" or "have" are intended to specify the existence of the described features, numbers, steps, actions, components, parts, or combinations thereof, and should not be understood as precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof. Furthermore, in carrying out the method or manufacturing method, each process constituting the method may occur in a different order than specified unless the context clearly indicates a specific order. That is, each process may occur in the same order as specified, may be performed substantially simultaneously, or may be performed in the reverse order.
[0069] The technology disclosed in this specification is not limited to the embodiments described herein and may be embodied in other forms. The embodiments introduced herein are provided merely to ensure that the disclosed content is thorough and complete, and to ensure that the technical concept of the technology is sufficiently conveyed to those skilled in the art. In the drawings, the dimensions, such as the width or thickness of each component, have been slightly enlarged to clearly represent the components of each device. The drawings are described from the perspective of an observer, and where one element is mentioned as being positioned above another element, this implies both that the element is positioned directly above the other element and that an additional element may be interposed between them. Furthermore, those skilled in the art may embody the concept of the invention in various other forms without departing from the technical concept of the invention. Also, in multiple drawings, the same reference numerals refer to substantially identical elements.
[0070] In this specification, the term "and / or" includes a combination of the plurality of described items or any one of the plurality of described items. In this specification, "A or B" may include "A," "B," or "both A and B."
[0071] In the present invention, the terms “individual(s),” “object(s),” and “patient(s)” refer to any mammal. In some embodiments, the mammal may be a human. In some embodiments, the mammal may not be a human. No term requires, or is not limited to, a situation characterized (e.g., constant or intermittent) by a healthcare worker (e.g., physician, licensed nurse, apprentice nurse, physician assistant, janitor, or hospice worker).
[0072] In the present invention, the term "treatment" refers to an attempt made with the intention of preventing the development or alteration of a lesion of a disease. Thus, "treatment" refers to both therapeutic and preventive aspects. Things requiring treatment include not only conditions where the disease is already present, but also conditions where the disease must be prevented. In the treatment of tumors, a therapeutic agent may mean directly reducing the pathology of tumor cells or making tumor cells more sensitive to treatment by other therapeutic agents, e.g., radiation and / or chemotherapy and / or immunotherapy. The terms "reduction" or "treated" as used herein mean an indication of approaching a normalized value measured by conventional statistical tests. An indication of approaching a normalized value may be, for example, a value that differs by less than 50% from a value obtained from a healthy patient or individual, preferably by less than 25%, more preferably by less than 10%, and even more preferably by no significant difference from the normalized value.
[0073] In the present invention, “treatment of cancer” means one or more of the following effects: 1) inhibition of tumor growth, including i) slowing or ii) complete cessation of growth; 2) reduction in the number of tumor cells; 3) maintenance of tumor size; 4) reduction in tumor size; 5) inhibition of tumor cell invasion into peripheral organs, including i) reduction or ii) slowing or iii) complete prevention; 6) inhibition of metastasis, including i) reduction or ii) slowing or iii) complete prevention; 7) enhancement of an anti-tumor immune response, which may cause i) maintenance of tumor size or ii) reduction in tumor size or iii) slowing of tumor growth or iv) reduction, slowing or prevention of invasion.
[0074] In this specification, when described as "C1-C5 alkyl," it means that the number of carbon atoms is 1 to 5. For example, C1-C3 alkyl means an alkyl having 1 to 3 carbon atoms, and C1-C5 alkyl means an alkyl having 1 to 5 carbon atoms.
[0075] In this specification, when described as “3 to 8 atoms of heterocycloalkyl,” it means a heterocycloalkyl having 3 to 8 atoms having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur.
[0076] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon radical. An alkyl may be a "saturated alkyl" that does not contain an alkenyl or alkynyl group, or an "unsaturated alkyl" that contains at least one alkenyl or alkynyl group. "Alkenyl" refers to a group containing at least one carbon-carbon double bond, and "alkynyl" refers to a group containing at least one carbon-carbon triple bond. When used alone or in combination, an alkyl may be cyclic, branched, or straight-chain, respectively. Representative saturated straight-chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The alkyl group may be optionally substituted.
[0077] The terms “halogen” and “halo” as used in this specification mean fluorine, chlorine, bromine, or iodine.
[0078] As used herein, the term “aryl” means a carbocyclic aromatic monocyclic group comprising six carbon atoms or a polycyclic group in which at least one ring is aromatic, which may be further fused to a second pentagonal or hexagonal carbocyclic group that may be aromatic, saturated, or unsaturated, either alone or in combination with other radicals. Representative examples of aryls include, but are not limited to, phenyl, tolyl, xylyl, naphthyl, tetrahydronaphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, etc. The aryl group may be optionally substituted and may be connected to another group at an appropriate position on the aromatic ring.
[0079] As used herein, "heteroaryl" is an aromatic heterocycle ring comprising at least one carbon atom having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, and comprising monocyclic and bicyclic ring systems. Preferably, the heteroaryl group may include, but is not limited to, a furyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a thiazolyl group, an oxazolyl group, an oxadiazolyl group, an oxadiazolyl group, a thiazolyl group, a thiazolyl group, an isothiazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a quinolinyl group, an isoquinolinyl group, a benzofuryl group, a benzothienyl group, an indolyl group, an indazolyl group, a quinoxalinyl group, a quinazolinyl group, a pyridopyrazinyl group, a benzoxadiazolyl group, a benzthiazolyl group, a benztriazolyl group, or a naphthiridinyl group. The heteroaryl group may be optionally substituted.
[0080] In the present invention, the term 'spiro compound' refers, unless otherwise noted, to a compound in which two rings among a cycloalkyl group and a heterocyclyl group are joined by sharing one atom. Preferably, the spiro compound may include a diazaspiro[5,5]undecane group and a diazaspiro[3,5]nonane group, but is not limited thereto.
[0081] As used herein, the term "cycloalkyl" means a monocyclic, spirocyclic, or polycyclic ring having carbon and hydrogen atoms, excluding aromatics. Examples of C3-C8 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Cycloalkyl groups may be optionally substituted.
[0082] As used herein, the term "heterocycloalkyl" means a monocyclic, spirocyclic, or polycyclic ring excluding aromatics having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur. Preferably, the heterocyclyl group may include a dioxalanyl group, a pyrrolyl group, an oxazolyl group, a thiazolyl group, an imidazolyl group, an oxadiazolyl group, a thiadiazolyl group, a triazolyl group, a triazinyl group, an isothiazolyl group, an isooxazolyl group, a thiophenyl group, a pyrazolyl group, a tetrazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a triazinyl group, or a tetrazinyl group, a pyrrolidinyl group, a furyl group, a morpholine group, a piperazinyl group, or a piperidinyl group, and more preferably may include a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a morpholine group, but is not limited thereto. The heterocycloalkyl group may be optionally substituted.
[0083] In this name, the term 'alkoxy' means an alkyl group (i.e., -O-alkyl) connected to another group through an oxygen atom. The alkoxy group may be unsubstituted or substituted with one or more suitable substituents. Examples of alkoxy groups include (C1-C6)alkoxy groups, e.g., -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-2-methyl-1-propyl, -O-2-methyl-2-propyl, -O-2-methyl-1-butyl, -O-3-methyl-1-butyl, -O-2-methyl-3-butyl, -O-2,2-dimethyl-1-propyl, -O-2-methyl-1-pentyl, 3-O-methyl-1-pentyl, -O-4-methyl-1-pentyl, -O-2-methyl-2-pentyl, -O-3-methyl-2-pentyl, -O-4-methyl-2-pentyl, -O-2,2-dimethyl-1-butyl, -O-3,3-dimethyl-butyl, -O-2-ethyl-1-butyl, -O-butyl, -O-isobutyl, -Ot-butyl, -O-pentyl, -O-isopentyl, -O-neopentyl, and -O-hexyl are included, but not limited to, -O-pentyl, -O-neopentyl, and -O-hexyl.
[0084] In the present invention, the term 'phenoxy' means a phenyl group (i.e., -O-aryl) connected to another group through an oxygen atom. The phenoxy group may be unsubstituted or substituted with one or more halogens; alkyl groups; aryl groups and heteroaryl groups, but is not limited thereto.
[0085] In the present invention, the term 'amino group' means an alkyl group (i.e., -NH- or -N-alkyl) connected to another group through a nitrogen atom. The amino group may be unsubstituted or substituted with one or more suitable substituents. Examples of amino groups include (C1-C6)amino groups, e.g., -NH-methyl, -NH-ethyl, -NH-propyl, -NH-isopropyl, -NH-2-methyl-1-propyl, -NH-2-methyl-2-propyl, -NH-2-methyl-1-butyl, -NH-3-methyl-1-butyl, -NH-2-methyl-3-butyl, -NH-2,2-dimethyl-1-propyl, -NH-2-methyl-1-pentyl, 3-NH-methyl-1-pentyl, -NH-4-methyl-1-pentyl, -NH-2-methyl-2-pentyl, -NH-3-methyl-2-pentyl, -NH-4-methyl-2-pentyl, -NH-2,2-dimethyl-1-butyl, -NH-3,3-dimethyl-butyl, -NH-2-ethyl-1-butyl, -NH-butyl, -NH-isobutyl, -NH-t-butyl, -NH-pentyl, -NH-isopentyl, -NH-neopentyl, -NH-hexyl, -N,N-dimethyl, -N-methyl-N-ethyl, -N-methyl-N-propyl, -N-methyl-isopropyl, -N-methyl-N-butyl, -N-methyl-N-isobutyl, -N-methyl-N-pentyl, -N-methyl-N-isopentyl, N-methyl-N-hexyl, N-methyl-N-isohexyl, -N,N-diethyl, -N-ethyl-N-propyl, -N-ethyl-N-isopropyl, -N-ethyl-N-butyl, -N-ethyl-N-isobutyl, -N-ethyl-N-pentyl, -N-ethyl-N-isopentyl, -N-ethyl-N-hexyl, , Includes, but is not limited to, -N-ethyl-N-isohexyl, -N,N-dipropyl, -N-propyl-N-isopropyl, -N-propyl-N-butyl, -N-propyl-N-isobutyl, -N-propyl-N-pentyl, -N-propyl-N-isopentyl, -N-propyl-N-hexyl, -N-propyl-N-isohexyl, -N,N-dibutyl, -N-butyl-N-isobutyl, -N-butyl-N-pentyl, -N-butyl-N-isopentyl, -N-butyl-N-hexyl, -N-butyl-N-isohexyl, -N,N-dipentyl, -N-pentyl-N-hexyl, -N-pentyl-N-isohexyl, -N,N-dihexyl
[0086] In the present invention, “-” expressed before or after a substituent signifies a “group.” For example, H2N-(C1-C3alkyl)- signifies an H2N-(C1-C3alkyl) group. Additionally, the “-” may signify a portion of the substituent that is bonded to another molecule.
[0087] In the present invention, the isomer refers to all of the structural isomer, cis-trans isomer, diastereomer, and optical isomer.
[0088] The present invention will be described in detail below.
[0089] The present invention relates to a conjugate of a urea derivative compound represented by the following chemical formula 1 and a compound selected from stereoisomers thereof.
[0090] [Chemical Formula 1]
[0091]
[0092] In the above Chemical Formula 1, a is an integer from 1 to 10; Ab is a CD33 antigen-specific binding antibody; L is a cleavable linker; and P is a payload having the characteristics of a neosubstrate degrader represented by the following Chemical Formula 2;
[0093] [Chemical Formula 2]
[0094]
[0095] In the above chemical formula 2, the above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13Each is independently hydrogen, an alkyl group, an aminoalkyl carbonyl group, an alkylaminoalkyl carbonyl group, a heterocycloalkyl carbonyl group, an aminoalkyl group, an alkylaminoalkyl group, a hydroxyalkyl carbonyl group, a cycloalkyl group, a halocycloalkyl group, a heterocycloalkyl group, a heterobicycloalkyl group, a cycloalkyl-alkyl group, a heterocycloalkyl-alkyl group, a hydroxycarbonylalkyl group, an alkylhydroxycarbonylalkyl group, an aminecarbonylalkyl group, or an alkylaminecarbonylalkyl group; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above alkyl group, cycloalkyl group, and heterocycloalkyl group of are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above A 2 is an alkyl group, an alkoxyalkyl group, an alkylaminocarbonylalkyl group, an alkylcarbonylaminoalkyl group, a carbonylalkyl group, an alkylaminoalkyl-alkyl group, an alcoholcy-alkoxyalkyl group, an alkylalkoxy-alkoxy group, or an alkylaminoalkyloxyalkyl group; and the above A 2 The above alkyl group and alkoxy group are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, an alkyl group, a hydroxyl group, an alkoxy group, an amine group, an alkylamine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or an alkyl group; and R 6 is hydrogen, deuterium, or an alkyl group; and the X 1 is NH, C(=O), O or CF2; and Y is O, S and NH.
[0096] In one aspect, the present invention,
[0097] The above binding moiety may be an antibody, an antibody fragment, or an antigen-binding fragment.
[0098] In addition, the protein to which the above-mentioned binding moiety binds may be a surface antigen, and the surface antigen may be CD33, but is not limited thereto.
[0099] Most preferably, the binding moiety may be an antibody that specifically binds to the CD33 antigen.
[0100] In one aspect, the present invention,
[0101] The above-mentioned cleavable linker may have a structure of the following chemical formula 3, 4, or 5.
[0102] [Chemical Formula 3]
[0103]
[0104] [Chemical Formula 4]
[0105]
[0106] [Chemical Formula 5]
[0107]
[0108] In the above chemical formulas 3, 4, and 5, represents the binding site with Ab; represents a binding site with a neo-substrate decomposer; W is -C(=O)-, -C(=O)NR'-, -NR'-, or -N(C=O)R', where R' is hydrogen, C 1-4 Alkylamino, -(CH2)nO(CH2)nNH2, -NH(CH2)2OC(O)NHSO2NH(CH2)2-, -NH(CH2)2OC(O)NHSO2NH(CH2)O(CH2)n- and; n is an integer from 1 to 10 and; Z 1 , Z 2 , Z 3 and Z 4 are either independently non-existent or are naturally occurring amino acid residues in the L- or D-set, and only Z 1 , Z 2 , Z 3 and Z 4At least two of them are amino acid residues; R 14 is either non-existent, C1~C3 alkoxy or -Ar-CH2OH-, and P is either non-existent or -(maleimide-N)- that binds to Ab.
[0109] In addition, the present invention, in one aspect,
[0110] The above Z 1 , Z 2 , Z 3 and Z 4 is not present independently or is selected from the group consisting of L-valine, D-valine, L-citrulline, D-citrulline, L-alanine, D-alanine, L-glutamine, L-glutamic acid, D-glutamic acid, D-glutamine, L-aspartic acid, D-aspartic acid, L-asparagine, D-asparagine, L-phenylalanine, D-phenylalanine, L-lysine, D-lysine, and glycine; provided, however, that Z 1 , Z 2 , Z 3 and Z 4 At least two of them may be amino acid residues.
[0111] More specifically
[0112] Z 1 is absent or is glycine;
[0113] Z 2 is absent, or is selected from the group consisting of L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-alanine, D-alanine, and glycine;
[0114] Z 3 is selected from the group consisting of L-valine, D-valine, L-alanine, D-alanine, L-phenylalanine, D-phenylalanine, and glycine;
[0115] Z 4 It can be selected from the group consisting of L-citrulline, D-citrulline, L-asparagine, D-asparagine, L-lysine, D-lysine, L-phenylalamine, D-phenylalanine, and glycine.
[0116] Also, the above Z 4 At the end of Z 5 It may include more, and Z 5 It may be absent or glycine.
[0117] Most preferably, the above chemical formula 4 may have the structure of the following chemical formula 6.
[0118] [Chemical Formula 6]
[0119]
[0120] In the above chemical formula 6, R14 is absent, C1~C3 alkoxy or -Ar-CH2OH-, and D is absent or -(maleimide-N)- bonded to Ab.
[0121] In one embodiment, the above D may have the structure of the following chemical formula 7 or 8.
[0122] [Chemical Formula 7]
[0123]
[0124] [Chemical Formula 8]
[0125]
[0126] In the above chemical formulas 7 and 8, m is an integer from 1 to 4; represents the binding site with Ab; * represents the binding site with W or an amino group.
[0127] In addition, the present invention, in one aspect,
[0128] The above W may have the structure of the following chemical formula 9 or 10.
[0129] [Chemical Formula 9]
[0130]
[0131] [Chemical Formula 10]
[0132]
[0133] In the above chemical formulas 9 and 10, * indicates a bonding site with P; R15 is bonded to a phenyl group, R15 is -NH- or -(OCH2CH2)nNH-; and n is an integer from 2 to 6.
[0134] In one aspect, the present invention,
[0135] The above R14 may have the structure of the following chemical formula 11 or 12.
[0136] [Chemical Formula 11]
[0137]
[0138] [Chemical Formula 12]
[0139]
[0140] In the above chemical formulas 11 and 12, represents the bonding point with the amino group; * represents the bonding point with D.
[0141] The above linker may specifically be selected and used from the following group.
[0142]
[0143] In the group of linkers mentioned above
[0144] Ab is a binding moiety that specifically binds to proteins; is a region connected to a neo-substrate decomposer; m is 1 to 4; and n is 1 to 4.
[0145] In one aspect of the present invention,
[0146] The above A of Chemical Formula 2 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; above R 7 , R 8 , R 9 , R 10 , R11 , R 12 and R 13 are each independently hydrogen, (C1-C5 alkyl) group, H2N-(C1-C5 alkyl)-C(=O)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-C(=O)-, (C3-C8 heterocycloalkyl)-C(=O)-, H2N-(C1-C5 alkyl)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-, HO-(C1-C5 alkyl)-C(=O)-, (C3-C8 cycloalkyl) group, (C3-C8 heterocycloalkyl) group, (C7-C 11 Heterobicycloalkyl) group, (C3-C8 cycloalkyl)-(C1-C5 alkyl)-, (C3-C8 heterocycloalkyl)-(C1-C5 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)-; and R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above (C1-C5 alkyl) group, (C3-C8 cycloalkyl) group and (C3-C8 heterocycloalkyl) group are substituted or unsubstituted with one or more selected from the group consisting of halogens and C1-C5 alkyls; and the above A 2 is -(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)HN-C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-C(=O)-NH(C1-C5alkyl)-, -C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-N(C1-C5alkyl)-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O- or -(C1-C5alkyl)HN-(C1-C5alkyl)-O-(C1-C5alkyl)-; and above A 2The above (C1-C5 alkyl) and (C1-C5 alkyl)-O are each independently substituted or unsubstituted with one or more selected from the group consisting of halogens and (C1-C5 alkyl); and the above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, a (C1-C5 alkyl) group, a hydroxyl group, an alkoxy group, an amine group, a (C1-C5 alkyl)amine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; and R 3 is hydrogen or a (C1-C5 alkyl) group; and R 6 is hydrogen, deuterium, or a (C1-C5 alkyl) group; and the X 1 is NH, C(=O), O or CF2; and Y is O, S or NH.
[0147] In one aspect of the present invention,
[0148] The above chemical formula 2 is the following chemical formula 2a or 2b;
[0149] [Chemical Formula 2a]
[0150]
[0151] [Chemical Formula 2b]
[0152]
[0153] In the above chemical formulas 2a and 2b, R 7 , R 8 , R 9 and R 10Each is independently hydrogen, (C1-C3 alkyl) group, H2N-(C1-C3 alkyl)-C(=O)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-C(=O)-, (C3-C6 heterocycloalkyl)-C(=O)-, H2N-(C1-C3 alkyl)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-, HO-(C1-C3 alkyl)-C(=O)-, (C3-C6 cycloalkyl) group, (C3-C6 heterocycloalkyl) group, (C7-C9 heterobicycloalkyl) group, (C3-C6 cycloalkyl)-(C1-C3 alkyl)-, (C3-C6 heterocycloalkyl)-(C1-C3 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)- and R 12 and R 13 It may be cyclic.
[0154] In one aspect of the present invention,
[0155] The above (C1-C3 alkyl) group, the above (C3-C6 cycloalkyl) group, or the above (C3-C6 heterocycloalkyl) group may be substituted or unsubstituted with one or more types selected from the group consisting of F, Cl, and (C1-C3 alkyl).
[0156] In one aspect of the present invention,
[0157] Above A 2 It may be -(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)HN-C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-C(=O)-NH(C1-C3alkyl)-, -C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-N(C1-C3alkyl)-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O- or -(C1-C3alkyl)HN-(C1-C3alkyl)-O-(C1-C3alkyl)-.
[0158] In one aspect of the present invention,
[0159] The above (C1-C3alkyl) and (C1-C3alkyl)-O may be substituted or unsubstituted with one or more types selected from the group consisting of F, Cl and (C1-C3alkyl).
[0160] In one aspect of the present invention,
[0161] The above R 1 , R 2 , R 4 and R 5 Each can independently be hydrogen, F, Cl, Br, (C1-C5 alkyl) group, hydroxyl group, alkoxy group, or trifluoromethyl group.
[0162] In one aspect of the present invention,
[0163] The above R 3 It can be hydrogen, methyl group, ethyl group, propyl group, or iso-propyl group.
[0164] In one aspect of the present invention,
[0165] The above R 6 It can be hydrogen, deuterium, or a methyl group.
[0166] In one aspect of the present invention,
[0167] The above X 1 It can be NH, C(=O), or CF2.
[0168] In one aspect of the present invention,
[0169] The above Y can be O or S.
[0170]
[0171] In one aspect of the present invention,
[0172] The compound of Chemical Formula 2 above may be any one selected from the group consisting of the following compounds.
[0173] 1-(3-chloro-4-(2-(2-((methyl I2-azanyl)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0174] 1-(4-(2-(2-axyloxyethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0175] 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide;
[0176] 1-(3-chloro-4-(2-((methylamino)oxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0177] 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea;
[0178] 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0179] 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0180] 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0181] N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylacetamide;
[0182] 2-(aminooxy)-N-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethyl)acetamide;
[0183] 1-(4-(2-(aminooxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0184] 2-amino-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenetoxy)acetamide;
[0185] 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0186] 3-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)propanamide;
[0187] 2-amino-N-(2-((2-((2-chloro-4-(3-((2-((2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenetoxy)amino)-2-oxoethyl)amino)-2-oxoethyl)acetamide
[0188] 2-(aminooxy)-N-(2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)amino)-2-oxoethyl)acetamide;
[0189] 2-(aminooxy)-N-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropyl)acetamide;
[0190] Ethyl 3-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)propaneoate;
[0191] 3-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)propanoic acid;
[0192] 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)acetamide;
[0193] 1-(3-chloro-4-(2-(2-((ethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride;
[0194] 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0195] 2-amino-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide;
[0196] 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0197] 1-(4-(2-(aminooxy)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea;
[0198] 1-(3-chloro-4-(2-(2-(hydroxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea;
[0199] 2-(aminooxy)-N-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)propyl)ureido)phenethyl)acetamide;
[0200] N-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenetoxy)azetidine-3-carboxaamide;
[0201] 2-(aminooxy)-N-(2-chloro-4-(3-((1R)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethoxy)acetamide;
[0202] 2-(aminooxy)-N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-2-methylpropyl)acetamide;
[0203] Ethyl 3-((2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)amino)propaneoate;
[0204] 2-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)acetamide;
[0205] 2-((2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)amino)acetamide;
[0206] 2-amino-N-(2-((2-((2-chloro-4-(3-((2-((2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenetoxy)amino)-2-oxoethyl)amino)-2-oxoethyl)acetamide hydrochloride;
[0207] Ethyl 3-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)propaneoate.
[0208]
[0209] In addition, the linker conjugate (LP) of the urea derivative compound of Chemical Formula 1 above may be one or more selected from the following group.
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217] At this time, in the above LP1~46, the bonding moiety can be bonded to the maleimide portion on the left side of the chemical formula.
[0218] The above binding moiety may be an antibody or an antigen-binding portion of an antibody. Additionally, the antibody may bind to a surface antigen. That is, if the binding moiety is an antibody, the binding moiety may bind to a surface antigen; and if the binding moiety is an antigen, it may have a form in which the antibody binds to the surface antigen and then the antibody is conjugated to the surface antigen.
[0219] The above surface antigen is a CD33 antigen-specific binding antibody; more preferably, the above surface antigen may be CD33.
[0220] The conjugate of the urea derivative compound according to the present invention can improve the neosubstrate degradation rate and maximum degradation capacity by specifically introducing a functional group of the -NO-, -ON-, or -NN- type at the structural end, thereby influencing the binding affinity between cereblon and the target protein, and consequently, the cancer cell killing effect can also be improved.
[0221] In the case of conventionally used compounds, the functional group at the structural end is an alkyl group or has oxygen or nitrogen independently in the alkyl group, but in the case of the present invention, as described above, it has a specific functional group containing nitrogen and oxygen consecutively at the structural end, so it can have higher activity compared to conventionally used compounds.
[0222] Generally, a neosubstrate refers to a protein that was not originally a substrate of E3 ubiquitin ligase, but becomes a new substrate of E3 ligase through specific technology (PROTAC, molecular glue, etc.) and is subsequently ubiquitinated and degraded.
[0223] Among various neosubstrates, for example, GSPT1 (G1 to S phase transition protein 1) has been identified as an oncogenic driver involved in various cellular processes such as cell cycle progression, cytoskeletal formation, and apoptosis. It is overexpressed in various types of cancer, including acute myeloid leukemia, gastric cancer, breast cancer, and liver cancer. Since reduced function and decreased expression of GSPT1 can inhibit tumor cell proliferation, migration, and invasion, GSPT1 is a promising target protein for anticancer drug development. However, designing traditional small molecule inhibitors for GSPT1 protein has been difficult due to the lack of well-defined binding pockets or active sites. Recently, however, GSPT1 protein degraders have been utilized as a powerful modality that degrades and removes GSPT1 protein through the ubiquitin-proteasome system (UPS) by acting as a molecular glue that induces interactions between GSPT1 protein and E3 ubiquitin ligase. When the GSPT1 protein is degraded, problems occur in the final stage of novel protein translation, which disrupts normal protein synthesis. Consequently, the resulting proteins are misfolded, mislocated, or have altered functions, causing serious homeostatic problems within the cell. This activates the Integrated Stress Response (ISR), and if the resulting changes in the expression of stress response genes exceed an internal threshold, apoptosis occurs.
[0224] That is, the conjugate of the urea derivative compound of the present invention degrades the neo-substrate as described above, and the finally degraded neo-substrate induces serious problems in the homeostasis of related proteins, thereby inducing the death of abnormal cells, particularly cancer cells.
[0225] The present invention also relates to a pharmaceutical composition for the prevention, alleviation, or treatment of cancer comprising the above-mentioned compound as an active ingredient.
[0226] In another aspect of the present invention,
[0227] The conjugate of the above pharmaceutical composition may have neo-substrate degrading activity.
[0228] In this specification, the treatment of cancer refers to the treatment of all cancer cells, and cancer includes the angiogenesis of endothelial cells and their mitosis (solid tumors, tumor metastasis, and benign tumors). For example, cancer may include, but is not limited to, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, genitourinary cancer, esophageal cancer, laryngeal cancer, glioblastoma, gastric cancer, skin cancer, keratosquamoma, lung cancer, squamous cell carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone cancer, colon cancer, adenoma, pancreatic cancer, adenocarcinoma, thyroid cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder cancer, liver cancer and biliary duct cancer, kidney cancer, myeloid disease, lymphoid disease, Hodgkin's disease, hair cell carcinoma, oral cancer, pharyngeal (oral) cancer, lip cancer, tongue cancer, small intestine cancer, colorectal cancer, colon cancer, rectal cancer, brain cancer, central nervous system cancer, leukemia, hemangioma, trachoma or pyogenic sarcoma. Preferably, it may be lymphoma, acute myeloid leukemia, multiple myeloma, or lung cancer, and two or more of the above cancers may develop simultaneously or sequentially.
[0229]
[0230] The present invention is also characterized by a method for preparing a compound represented by the above chemical formula 1.
[0231] In addition, the compound represented by Formula 2 of the present invention may be prepared by the following reaction formulas 1 to 9 or by the method described in the examples. However, the following reaction formulas 1 to 9 are merely examples for explaining the method of preparing Formula 2, and the method of preparing Formula 1 of the present invention is not limited to these reaction formulas.
[0232] [Reaction Equation 1]
[0233]
[0234] Compound 1-2 was obtained by reducing compound 1-1 with borane, and compound 1-4 was obtained through substitution and reduction reactions, after which compound 1-5 was obtained by reducing the nitro group with iron. Compound 1-6 was obtained by introducing a protecting group to the amine group using phthalic anhydride, and then compound 1-7 was obtained by introducing a leaving group using methanesulfonyl chloride, followed by substitution with a hydroxycarbamate to obtain compound 1-8. Compound 1-9 was obtained by removing the protecting group using hydrazine, followed by obtaining urea-type compound 1-11 using diphosgene, and then compound P1 was obtained by removing the protecting group under acidic conditions, and compounds P2, P12, P26, P28, P29, P33, and P36 were obtained in a similar manner.
[0235] [Reaction Equation 2]
[0236]
[0237] Compound 2-3 was obtained by methylation of Compound 2-1 using methyl chloride, followed by the use of 2-hydroxyisoindolin-1,3-dione, and 80 using hydrazine o After obtaining compound 2-4 by removing the protecting group from C, compound 2-6 and compound 1-10 were obtained in the same manner as reaction scheme 1, in which compound 2-5 was obtained using a water bath under basic conditions, and then compound 2-7 in the form of a thiourea was obtained using di(1H-imidazole-1-yl)methanethio, and then compound P5 was obtained by removing the protecting group under acidic conditions, and compounds P14 and P23 were obtained in a similar manner.
[0238] [Reaction Equation 3]
[0239]
[0240] Compound 3-4 was obtained by introducing a leaving group to Compound 3-1 and substituting Compound 3-3, and then Compound 3-6 was obtained by removing the protecting group using hydrazine. Compound 3-7 was obtained using a water-based solution, and then Compound P3 was obtained in the same manner as in Reaction Scheme 1, and Compounds P11, P15, and P17 were obtained in a similar manner.
[0241] [Reaction Equation 4]
[0242]
[0243] Compound 4-2 was obtained from Compound 4-1 via Stille cross-coupling, and Compound 4-3 was selectively obtained using (R)-2-methylpropane-2-sulfonamide. After removing the sulfonate group under acidic conditions, Compound 4-5 was obtained using a hydrochloric acid. Compound 4-6 was obtained through hydrolysis, and an ester form of Compound 4-6 was obtained using (trimethylsilyl)diazomethane. The hydroxyl group was then substituted with bromine. Compound 4-10 was obtained through a chain substitution and cyclization reaction using Compound 4-9, and Compound 4-11 was obtained by removing the protecting group under acidic conditions. Compound 4-13 was obtained by substituting dimethyl malonate into Compound 4-12, and Compound 4-14 was obtained through a decarboxylation reaction. Compound 4-15 was obtained by substituting a methyl group. After obtaining compound 4-18 through reduction, substitution, and reduction reactions, compound 4-19 was obtained through the Mitsunobu reaction, and then compound 4-20 was obtained by reducing it with iron. Compound 4-21 in the urea form was obtained using phenylchloroformate, and then compound P6 was obtained by removing the protecting group with acid, and compounds P7, P25, and P31 were obtained in a similar manner.
[0244] [Reaction Equation 5]
[0245]
[0246] Compound 5-1 was obtained by introducing a methylate with compound 4-18 and compound 5-2 was obtained through a substitution reaction, compound 5-3 was obtained through a reduction reaction using iron, compound 5-4 in the form of urea was obtained using phenylchloroformate, and then the protecting group was removed with acid to obtain compound P9, and compounds P8 and P27 were obtained in a similar manner.
[0247] [Reaction Equation 6]
[0248]
[0249] Compound 6-2 was obtained through amide coupling with compound P12 and compound 6-1 glycolic acid, and compound P13 was obtained by removing the protecting group with acid. In a similar manner, compounds P10, P16, P19, P20, P29, P30, P32, P33, P34, P35, and P36 were obtained.
[0250]
[0251] Hereinafter, preferred embodiments of the present invention will be described with reference to the accompanying drawings so that those skilled in the art can easily implement them. Furthermore, in describing the present invention, if it is determined that a detailed description of related known functions or known configurations may unnecessarily obscure the essence of the invention, such detailed description will be omitted. Also, some features presented in the drawings have been enlarged, reduced, or simplified for ease of explanation, and the drawings and their components are not necessarily depicted in appropriate proportions. However, those skilled in the art will easily understand these details.
[0252] Payload (P) Synthesis
[0253] The chemical structures of the payloads (P1 to P35) prepared in Examples 1 to 35 below are summarized as follows.
[0254]
[0255]
[0256]
[0257] In the case of the representative payload 1 (P1) below, it was synthesized in the same way as the previously filed patent (Application No. 10-2025-0063578).
[0258] Example 1: Synthesis of P1
[0259]
[0260] Step 1: Synthesis of 2-(2-chloro-4-nitrophenyl)ethanol-1-ol
[0261] Borein dimethyl sulfide complex (10.00 M solution in THF, 5.798 mL, 57.980 mmol) was added to a solution of 2-(2-chloro-4-nitrophenyl)acetic acid (5.000 g, 23.192 mmol) dissolved in tetrahydrofuran (100 mL) at 0 °C, and the mixture was heated under reflux for 2 hours, after which the temperature was lowered to room temperature to terminate the reaction. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 20% to 70%) to obtain 2-(2-chloro-4-nitrophenyl)ethanol-1-ol (4.100 g, 87.7%) in the form of a light brown solid.
[0262]
[0263] Step 2: Synthesis of tert-butyl 2-(2-chloro-4-nitropenetoxy)acetate
[0264] A mixture of 2-(2-chloro-4-nitrophenyl)ethanol-1-ol (4.100 g, 20.336 mmol), tert-butyl 2-bromoacetate (11.930 mL, 81.345 mmol), and tetrabutylammonium hydrogen sulfate (5.524 g, 16.269 mmol) in toluene (40 mL) was stirred at room temperature for 30 hours, and sodium hydroxide (NaOH, 5.00 M solution in water, 366.053 mL, 1.830 mol) was added and stirred for an additional 2 hours at the same temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 0% to 20%) to obtain tert-butyl 2-(2-chloro-4-nitropenetoxy)acetate (4.500 g, 70.1%) in the form of a yellow liquid.
[0265]
[0266] Step 3: Synthesis of 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol
[0267] Diisobutyl aluminum hydride (DIBAL, 1.00 M solution in THF, 31.354 mL, 31.354 mmol) was added to a solution of tert-butyl 2-(2-chloro-4-nitropenetoxy)acetate (4.500 g, 14.252 mmol) dissolved in tetrahydrofuran (100 mL) at 0 °C, and the mixture was stirred at room temperature for 18 hours. Subsequently, water (5.136 mL, 285.036 mmol) was added to the reaction mixture at 0 °C and stirred for 30 minutes to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and a saturated aqueous sodium bicarbonate solution was poured into the filtrate and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 25 g cartridge; ethyl acetate / hexane = 20% to 60%) to obtain 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol (2.360 g, 67.4%) in the form of a yellow liquid.
[0268]
[0269] Step 4: Synthesis of (2-(4-amino-2-chlorophennetoxy)ethanol-1-ol
[0270] A mixture of 2-(2-chloro-4-nitropenetoxy)ethanol-1-ol (1.020 g, 4.729 mmol), ammonium chloride (1.518 g, 28.375 mmol), and iron (2.641 g, 47.292 mmol) was mixed in water (3 mL) and ethanol (15 mL) at room temperature and stirred at 80 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. The reaction mixture was filtered through a Celite pad to remove the solid, and the filtrate was subjected to solvent removal under reduced pressure to obtain a concentrate. A saturated aqueous sodium bicarbonate solution was poured over the concentrate, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The yellow liquid product (0.715 g, 70.1%) was used without further purification.
[0271]
[0272] Step 5: Synthesis of (2-(3-chloro-4-(2-(2-hydroxyethoxy)ethyl)phenyl)isoindolin-1,3-dione
[0273] A mixture of 2-(4-amino-2-chlorophennetoxy)ethanol-1-ol (0.715 g, 2.911 mmol) and isobenzofuran-1,3-dione (0.431 g, 2.911 mmol) was mixed in acetic acid (5 mL) at room temperature and stirred at 120 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. A saturated aqueous sodium bicarbonate solution was poured over the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The brown liquid product (1.0 g, 99.4%) was used without further purification.
[0274]
[0275] Step 6: Synthesis of 2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethyl methanesulfonate
[0276] To a solution in which 2-(3-chloro-4-(2-(2-hydroxyethoxy)ethyl)phenyl)isoindoline-1,3-dione (1.000 g, 2.892 mmol) was dissolved in dichloromethane (20 mL) at room temperature, methanesulfonyl chloride (0.336 mL, 4.338 mmol) and N,N-diisopropylethylamine (1.511 mL, 8.676 mmol) were added and stirred at the same temperature for 2 hours. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain the title compound (0.856 g, 69.8%) in the form of a brown solid.
[0277]
[0278] Step 7: Synthesis of tert-butyl (2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethoxy)(methyl)carbamate
[0279] Sodium hydride (NaH, 60.00%, 0.089 g, 2.221 mmol) was added to a solution of tert-butyl hydroxy(methyl)carbamate (0.357 g, 2.423 mmol) dissolved in DMF (15 mL) at 0 °C, and the mixture was stirred for 30 minutes at the same temperature. 2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethyl methanesulfonate (0.856 g, 2.020 mmol) was added to the reaction mixture, and the mixture was further stirred for 18 hours at room temperature. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 10% to 40%) to obtain the title compound (0.267 g, 27.8%) in the form of a brown liquid.
[0280]
[0281] Step 8: Synthesis of tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate
[0282] Hydrazine monohydrate (0.055 mL, 1.124 mmol) was added to a solution of tert-butyl (2-(2-chloro-4-(1,3-dioxoisoindolin-2-yl)phennetoxy)ethoxy)(methyl)carbamate (0.267 g, 0.562 mmol) dissolved in ethanol (10 mL) at room temperature, and the mixture was stirred at 60 °C for 1 hour, after which the temperature was lowered to room temperature to terminate the reaction. A saturated aqueous sodium bicarbonate solution was poured over the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain the title compound (0.106 g, 54.7%) in the form of a yellow liquid.
[0283]
[0284] Step 9: Synthesis of tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate
[0285] Trichloromethyl carbonochloridate (0.074 mL, 0.615 mmol) was added to a solution of tert-butyl (2-(4-amino-2-chlorophennetoxy)ethoxy)(methyl)carbamate (0.106 g, 0.307 mmol) dissolved in tetrahydrofuran (5 mL) at room temperature, stirred for 1 hour at the same temperature, and then concentrated. 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.07 M solution in DMF, 5.270 mL, 0.369 mmol) and triethylamine (0.428 mL, 3.074 mmol) were added to the reaction mixture and stirred for an additional 1 hour at the same temperature. A saturated aqueous sodium bicarbonate solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 5 g cartridge; methanol / dichloromethane = 0% to 10%) to obtain the title compound (0.089 g, 45.0%) in the form of a bright yellow liquid.
[0286]
[0287] Step 10: Synthesis of 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea, P1
[0288] tert-butyl (2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)ethoxy)(methyl)carbamate)0.089 g, 0.138 mmol) was dissolved in trifluoroacetic acid (1 mL) / dichloromethane (3 mL) at room temperature and stirred for 30 minutes at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid = 0% to 70%) to obtain the title compound (0.020 g, 26.6%) in the form of a white solid.
[0289] 1H-NMR (400 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.73 (s, 1H), 7.64 (m, 2H), 7.47 (s, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.4, 2.0 Hz, 1H), 6.76 (t, J = 6.0 Hz, 1H), 6.45 (bs, 1H), 5.06 (dd, J = 13.2, 4.8 Hz, 1H), 4.43 - 4.25 (m, 4H), 3.60 (t, J = 4.8 Hz, 2H), 3.52 - 3.46 (m, 4H), 2.87 - 2.58 (m, 6H), 2.36 (m, 2H), 1.96 (m, 1H); LRMS (ES) m / z 544.2 [M+H].
[0290]
[0291] Example 2: Synthesis of P2
[0292] 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride was synthesized in a manner similar to P1.
[0293] 1H-NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 10.68 (s, 1H), 9.01 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.18 (dd, J = 8.4, 2.0 Hz, 1H), 6.95 (t, J = 6.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.47 - 4.29 (m, 4H), 4.12 - 4.07 (m, 2H), 3.66 - 3.63 (m, 2H), 3.57 (t, J = 3.5 Hz, 2H), 2.96 - 2.88 (m, 1H), 2.86 (t, J = 7.2 Hz, 2H), 2.69 - 2.56 (m, 1H), 2.44 - 2.30 (m, 1H), 2.06 - 1.95 (m, 1H); LRMS (ES) m / z 530.2 [M+H]+.
[0294]
[0295] Example 3: Synthesis of P3
[0296] 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide was synthesized in a manner similar to P1.
[0297] tert-butyl (2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)amino)-2-oxoethoxy)carbamate (0.014 g, 0.021 mmol) was dissolved in trifluoroacetic acid (1 mL) / dichloromethane (2 mL) at 0 °C and stirred for 2 hours at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 5 g cartridge; acetonitrile / 0.1% aqueous formic acid = 0% to 60%) to obtain the title compound (0.011 g, 95.8%) in the form of a white solid.
[0298] 1H NMR (400 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.76 (s, 1H), 7.81 (t, J = 5.9 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.63 (s, 1H), 7.47 (s, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.12 (s, 1H), 7.12 (s, 1H), 6.79 (t, J = 6.0 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.46 - 4.22 (m, 4H), 3.88 (s, 2H), 2.95 - 2.80 (m, 1H), 2.74 (t, J = 7.3 Hz, 2H), 2.67 - 2.51 (m, 1H), 2.43 - 2.25 (m, 1H), 2.02 - 1.89 (m, 3H); LRMS (ES) m / z 543.2 [M+H]+.
[0299]
[0300] Examples 4~10: Synthesis of P4~P10
[0301] It was synthesized using a method similar to the synthesis method of P1.
[0302] 실시예1H-NMR (400 MHz, DMSO-d6), LRMS (ES) m / z [M+H]+4δ 10.97 (s, 1H), 8.58 (d, J = 3.4 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 2.1 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 6.84 (dd, J = 7.5, 2.6 Hz, 1H), 5.10 (dd, J = 13.2, 5.0 Hz, 1H), 4.90 (p, J = 6.6 Hz, 1H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.73 (t, J = 7.0 Hz, H, 2H), 2.96 - 2.86 (m, 1H), 2.84 (t, J = 7.0 Hz, 2H), 2.69 - 2.56 (m, 1H), 2.53 (s, 3H), 2.46 - 2.31 (m, 1H), 1.99 (ddd, J = 9.8, 5.1, 2.5 Hz, 1H), 1.42 (d, J = 7.0 Hz, 3H); LRMS (ES) m / z 514.1 [M+H]+5δ 10.96 (s, 1H), 9.94 (br, 1H), 8.54 (br, 1H), 7.82 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.1 Hz,1H), 7.42 (s, 1H), 5.09 (dd, J = 13.3, 4.8 Hz, 1H), 4.91 (s, 2H), 4.85 (br, 2H), 4.37(dd, J = 55.2, 17.3 Hz, 2H), 2.99 - 2.52 (m, 2H), 2.22 (ddd, J = 135.2, 11.8, 4.8 Hz, 2H); LRMS (ES) m / z 488.0 [M+H]+6δ 10.94 (s, 1H), 8.51 (d, J = 3.5 Hz, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 2.3 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.06 (dd, J = 8.7, 2.4 Hz, 1H), 6.77 (dd, J = 7.6, 2.7 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.86 (p, J = 7.0 Hz, 1H), 4.41 (d, J = 17.6 Hz, 1H), 4.28 (d, J = 17.3 Hz, 1H), 3.62 (s, 2H), 3.39 (t, J = 5.8 Hz, 2H), 3.30 (s, 3H), 2.92 - 2.84 (m, 1H), 2.81 (t, J = 5.9 Hz, 2H), 2.63 - 2.52 (m, 1H), 2.42 - 2.27 (m, 1H), 1.99 - 1.91 (m, 1H), 1.38 (dd, J = 6.9, 1.1 Hz, 3H), 1.31 (s, 6H); LRMS (ES) m / z 586.3 [M+H]+7δ 10.97 (s, 1H), 8.60 (d, J = 3.6 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.10 (dd, J = 8.7, 2.3 Hz, 1H), 6.87 (dd, J = 7.5, 12.8 Hz, 1H), 5.10 (dd, J = 13.2, 5.0 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.45 (d, J = 17.2 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 3.66 (s, 2H), 3.60 - 3.55 (m, 2H), 3.51 - 3.46 (m, 2H), 2.96 - 2.85 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 - 2.31 (m, 1H), 2.04 - 1.95 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 572.2 [M+H]+8δ 10.97 (s, 1H), 8.54 (d, J = 2.9 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 7.09 (dd, J = 8.5, 1.7 Hz, 1H), 6.80 (dd, J = 7.5, 1.9 Hz, 1H), 5.10 (dd, J = 13.1, 4.9 Hz, 1H), 4.91 (p, J = 6.8 Hz, 1H), 4.45 (d, J = 17.2 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.67 (s, 2H), 3.64 - 3.59 (m, 2H), 3.51 - 3.43 (m, 2H), 2.97 - 2.84 (m, 1H), 2.64 - 2.55 (m, 1H), 2.43 (s, 3H), 2.42 - 2.32 (m, 1H), 2.04 - 1.94 (m, 1H), 1.42 (d, J = 6.7 Hz, 3H), 1.35 (s, 6H); LRMS (ES) m / z 586.2 [M+H]+9LRMS (ES) m / z [M+H]+ 586.310δ 10.97 (s, 1H), 8.60 (d, J = 3.6 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 2.4 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 7.10 (dd, J = 8.7, 2.4 Hz, 1H), 6.86 (dd, J = 7.5, 2.7 Hz, 1H), 5.10 (dd, J = 13.2, 4.8 Hz, 1H), 4.90 (p, J = 7.0 Hz, 1H), 4.58 (t, J = 6.1 Hz, 1H), 4.45 (d, J = 17.7 Hz, 1H), 4.31 (d, J = 17.7 Hz, 1H), 4.12 (d, J = 6.0 Hz, 2H), 3.93 - 3.88 (m, 2H), 3.69 (s, 2H), 3.54 - 3.50 (m, 2H), 3.03 (s, 3H), 2.96 - 2.85 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 - 2.32 (m, 1H), 2.03 - 1.95 (m, 1H), 1.41 (d, J = 6.8 Hz, 3H), 1.38 (s, 6H); LRMS (ES) m / z 644.2 [M+H]+.
[0303]
[0304] Examples 11–35: Synthesis of P11–P35
[0305] It was synthesized using a method similar to the synthesis method of P1.
[0306] Example LRMS (ES) m / z [M+H]+11557.212486.213543.214472.115557.216657.317600.318585.319630.220602.321559.222657.323486.224527.325544.226500.227530.328571.229569.230573.231571.232672.333587.134629.335588.1
[0307]
[0308] Linker-Payload (LP1~LP46) Synthesis
[0309] Example 36: Synthesis of LP1
[0310]
[0311] Step 1: Synthesis of (2S,3R,4S,5S,6S)-2-(2-((benzyloxy)carbonyl)-4-formylphenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
[0312] The title compound (0.290 g, 98.3%, white solid) was obtained from the starting material of LP3-1 according to the synthesis method of WO201818234. LRMS (ES) m / z 507.0 [M+Na] + .
[0313]
[0314] Step 2: Synthesis of (2S,3R,4S,5S,6S)-2-(2-((benzyloxy)carbonyl)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate
[0315] Sodium borohydride (1.155 g, 30.532 mmol) was added to a solution of (2S,3R,4S,5S,6S)-2-(2-((benzyloxy)carbonyl)-4-formylphenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (8.74 g, 15.266 mmol) dissolved in 2-propanol (24 mL) / chloroform (120 mL) at 0 °C, and the mixture was stirred at the same temperature for 2 hours. Then, water (55.018 mL, 3.053 mol) was added to the reaction mixture and stirred for 10 minutes to terminate the reaction. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated aqueous solution of water, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. Diethyl ether (30 mL) was poured over the concentrate to suspend it, and after filtration, the resulting solid was dried to obtain the title compound (7.60 g, 86.7%). LRMS (ES) m / z 597.0 [M+Na]+.
[0316]
[0317] Step 3: Synthesis of 5-(hydroxymethyl)-2-(((2S,3R,4S,5S,6S)-3,4,5-triacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)oxy)benzoic acid
[0318] (2S,3R,4S,5S,6S)-2-(2-((benzyloxy)carbonyl)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.350 g, 0.609 mmol) was added to a solution dissolved in ethanol (5 mL) at room temperature and stirred for 10 minutes at the same temperature. The reaction mixture was filtered through a Celite pad to remove the solid, and the filtrate was subjected to solvent removal under reduced pressure to obtain the title compound (0.290 g, 98.3%) as a white solid, which was used without further purification. LRMS (ES) m / z 507.0 [M+Na]+.
[0319]
[0320] Step 4: Synthesis of (2S,3R,4S,5S,6S)-2-(2-((allyloxy)carbonyl)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate
[0321] A solution of 5-(hydroxymethyl)-2-(((2S,3R,4S,5S,6S)-3,4,5-triacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)oxy)benzoic acid (0.310 g, 0.640 mmol), allyl bromide (0.061 mL, 0.704 mmol), and potassium carbonate (K2CO3, 0.265 g, 1.920 mmol) dissolved in N,N-dimethylformamide (5 mL) at room temperature was stirred at the same temperature for 3 hours. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution, moisture was removed with anhydrous magnesium sulfate, and the solution was filtered and concentrated under reduced pressure to obtain the title compound (0.310 g, 92.4%) as white crystals, which were used without further purification. LRMS (ES) m / z 547.0 [M+Na]+.
[0322]
[0323] Step 5: Synthesis of (2S,3R,4S,5S,6S)-2-(2-((allyloxy)carbonyl)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate
[0324] A solution of (2S,3R,4S,5S,6S)-2-(2-((allyloxy)carbonyl)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.350 g, 0.667 mmol), bis(4-nitrophenyl) carbonate (0.203 g, 0.667 mmol), and N,N-diisopropylethylamine (0.117 mL, 0.667 mmol) dissolved in N,N-dimethylformamide (5 mL) was stirred at 0 °C for 30 minutes and further stirred at room temperature for 1 hour. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution, water was removed with anhydrous magnesium sulfate, and the solution was filtered and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 40%) to obtain the title compound (0.330 g, 71.7%) in the form of yellow crystals. LRMS (ES) m / z 712.2 [M+Na]+.
[0325]
[0326] Step 6: Synthesis of (2S,3R,4S,5S,6S)-2-(2-((allyloxy)carbonyl)-4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
[0327] (2S,3R,4S,5S,6S)-2-(2-((allyloxy)carbonyl)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.330 g, 0.479 mmol), 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.250 g, 0.431 mmol) and 1H-benzo[d][1,2,3]triazole-1-ol (HOBt, 0.012 g, N,N-diisopropylethylamine (0.150 mL, 0.861 mmol) was added to a solution prepared by dissolving 0.086 mmol) in N,N-dimethylformamide (5 mL) at 0 °C, and the mixture was stirred at the same temperature for 24 hours. Water was added to the concentrate obtained by removing the solvent from the reaction mixture under reduced pressure, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / 10% aqueous ethyl acetate solution = 0% to 10%) to obtain the title compound (0.500 g, 95.5%) in the form of white crystals. LRMS (ES) m / z 1116.4 [M+Na]+.
[0328]
[0329] Step 7: Synthesis of 5-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(((2S,3R,4S,5S,6S)-3,4,5-triacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)oxy)benzoic acid
[0330] (2S,3R,4S,5S,6S)-2-(2-((allyloxy)carbonyl)-4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.100 g, 0.091 mmol), pyrrolidine (0.009 mL, 0.110 mmol), triphenylphosphine (0.006 g, 0.023 mmol) and tetrakis(triphenylphosphine)palladium (0.004 g, 0.004 A solution of mmol dissolved in dichloromethane (2 mL) at room temperature was stirred at the same temperature for 2 hours. A 1N aqueous hydrochloric acid solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous water solution, water was removed with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. A 100% aqueous diethyl ether solution (20 mL) was poured into the concentrate to suspend it, and after filtration, the resulting solid was washed with hexane and dried to obtain the title compound (0.070 g, 72.7%) in the form of milky white crystals. LRMS (ES) m / z 1076.0 [M+Na]+.
[0331]
[0332] Step 8: Synthesis of (2S,3R,4S,5S,6S)-2-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecane-13-yl)carbamoyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
[0333] 5-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(((2S,3R,4S,5S,6S)-3,4,5-triacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)oxy)benzoic acid (0.070 g, 0.066 mmol), tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.019 mL, 0.080 mmol), A solution of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 0.030 g, 0.080 mmol) and N,N-diisopropylethylamine (0.017 mL, 0.100 mmol) dissolved in N,N-dimethylformamide (1 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 2 hours. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; methanol / ethyl acetate = 0% to 10%) to obtain the title compound (0.068 g, 79.7%) in the form of white crystals. LRMS (ES) m / z 1306.5 [M+Na]+.
[0334]
[0335] Step 9: Synthesis of (2S,3S,4S,5R,6S)-6-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecane-13-yl)carbamoyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
[0336] (2S,3R,4S,5S,6S)-2-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecane-13-yl)carbamoyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.030 g, 0.023 mmol), lithium hydroxide (LiOH, 0.002 g, 0.070 mmol) and tetramethylammonium A solution of hydroxide (25.00% solution, 0.059 mL, 0.163 mmol) dissolved in 2-propanol (3 mL), tetrahydrofuran (1 mL), and water (1 mL) was stirred at -40 °C for 10 minutes and further stirred at -10 °C for 1 hour. Afterward, the reaction was terminated by adding acetic acid (0.011 mL, 0.187 mmol) to the reaction mixture at -10 °C to neutralize it. The solvent was removed from the reaction mixture under reduced pressure to obtain the title compound, which was used without further purification. LRMS (ES) m / z 1166.0 [M+Na]+.
[0337]
[0338] Step 10: (2S,3S,4S,5R,6S)-6-(2-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)-4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid hydrochloride
[0339] (2S,3S,4S,5R,6S)-6-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecane-13-yl)carbamoyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (0.027 g, 0.024 mmol) and hydrochloric acid (4.00 M solution, 0.118 mL, 0.472 mmol) were mixed in dichloromethane (2 mL). The dissolved solution was stirred at 0 °C for 30 minutes and further stirred at room temperature for 30 minutes. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (Waters, C18; acetonitrile / 0.1% aqueous formic acid = 10% to 70%) to obtain the title compound (0.012 g, 47.1%). LRMS (ES) m / z 1044.0 [M+H]+.
[0340]
[0341] Step 11: Synthesis of (2S,3S,4S,5R,6S)-6-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-((2-(2-(2-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)propamido)ethoxy)ethoxy)ethyl)carbamoyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
[0342] (2S,3S,4S,5R,6S)-6-(2-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)-4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid hydrochloride (0.012 g, 0.011 mmol), 2,5-dioxopyrrolidine-1-yl A solution of 3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)propanoate (0.004 g, 0.013 mmol) and N,N-diisopropylethylamine (0.004 mL, 0.022 mmol) dissolved in N,N-dimethylformamide (1 mL) was stirred at 0 °C for 10 minutes and further stirred at room temperature for 1 hour. The reaction mixture was purified and concentrated by column chromatography (Waters, C18; acetonitrile / 0.1%-aqueous formic acid = 10% to 50%) to obtain the title compound (0.005 g, 37.7%).
[0343] 1H NMR (400 MHz, DMSO-d6)δ 10.97 (s, 1H), 8.79 (s, 1H), 8.31 (t, J = 5.7 Hz, 1H), 8.00 (t, J = 5.7 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.71 - 7.64 (m, 2H), 7.53 - 7.42 (m, 3H), 7.23 (dd, J = 18.8, 8.4 Hz, 2H), 7.14 (dd, J = 8.4, 2.1 Hz, 1H), 6.99 (s, 2H), 6.82 (t, J = 5.9 Hz, 1H), 5.16 - 5.07 (m, 4H), 4.39 (dt, J = 45.5, 17.4 Hz, 4H), 3.97 (d, J = 9.4 Hz, 1H), 3.94 - 3.90 (m, 2H), 3.65 - 3.48 (m, 18H), 3.14 (q, J = 5.7 Hz, 2H), 3.05 (s, 3H), 2.97 - 2.87 (m, 1H), 2.83 (t, J = 7.0 Hz, 2H), 2.69 - 2.55 (m, 1H), 2.46 - 2.34 (m, 3H), 2.33 (dd, J = 9.1, 5.4) Hz, 3H), 2.05 - 1.93 (m, 1H), 1.24 (s, 1H); LRMS (ES) m / z 1217.3 [M+Na]+.
[0344]
[0345] Example 36: Synthesis of LP2
[0346] LP2 was synthesized in a similar way to LP1.
[0347] LRMS (ES) m / z 1149.63 [M+H]+,1171.49[M+Na]+.
[0348]
[0349] Example 37: Synthesis of LP42
[0350] LP42 was synthesized in a similar way to LP1.
[0351] LRMS (ES) m / z 1151.69 [M+H]+,1173.47[M+Na]+.
[0352]
[0353] Example 38: Synthesis of LP3
[0354] LP2 was synthesized in a similar way to LP1.
[0355] LRMS (ES) m / z 1135.52 [M+H]+.
[0356]
[0357] Example 39: Synthesis of LP4
[0358] LP4 was synthesized in a similar way to LP1.
[0359] LRMS (ES) m / z 1261.0 [M+Na]+.
[0360]
[0361] Example 40: Synthesis of LP5
[0362]
[0363] Step 1: Synthesis of ((2S,3R,4S,5S,6S)-2-(2-amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
[0364] (2S,3R,4S,5S,6S)-2-(4-(hydroxymethyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (3.000 g, 6.184 mmol) and zinc (11.873 g, 185.521 mmol) were dissolved in acetic acid (10 mL) / methanol (15 mL) and stirred at 0 °C for 30 minutes, and then further stirred at room temperature for 1 hour. The reaction mixture was subjected to solvent removal under reduced pressure to obtain a concentrate to which an aqueous solution of N-sodium bicarbonate was poured, and the mixture was extracted with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, and the solution was filtered and concentrated under reduced pressure to obtain the title compound (2.650 g, 94.1%) as a beige solid, which was used without further purification. LRMS (ES) m / z 456.1 [M+H]+.
[0365]
[0366] Step 2: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecane-17-amido)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
[0367] (2S,3R,4S,5S,6S)-2-(2-amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.200 g, 0.439 mmol), 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecan-17 acid (0.151 mL, 0.527 mmol), and ethyl 2-ethoxyquinoline-1(2H)-carboxylate (0.326 g, 1.317 mmol) were dissolved in dichloromethane (2 mL) at room temperature and stirred for 16 hours at the same temperature. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 80%) to obtain the title compound (0.326 g, 98.0%) as a pale orange oil. LRMS (ES) m / z 759.1 [M+H]+.
[0368]
[0369] Step 3: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecan-17-amido)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate
[0370] (2S,3R,4S,5S,6S)-2-(2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecane-17-amido)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.326 g, 0.430 mmol), bis(4-nitrophenyl) carbonate (0.144 g, 0.473 mmol), and N,N-diisopropylethylamine (0.150 mL, 0.860 mmol) were dissolved in N,N-dimethylformamide (3 mL) and stirred at 0 °C for 30 minutes, followed by further stirring at room temperature for 2 hours. Water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 70%) to obtain the title compound (0.301 g, 75.8%) as a pale yellow oil. LRMS (ES) m / z 946.0 [M+Na]+.
[0371]
[0372] Step 4: Synthesis of (2S,3R,4S,5S,6S)-2-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecane-17-amido)phenoxy)-6-(methoxycarbonyl)tetrahydro2H-pyran-3,4,5-triyl triacetate
[0373] (2S,3R,4S,5S,6S)-2-(2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecan-17-amido)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.301 g, 0.326 mmol), 1-(3-chloro-4-(2-(2-((methylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride (0.189 g, 0.326 mmol), A solution of 1-hydroxybenzotriazole hydrate (0.044 g, 0.326 mmol) and N,N-diisopropylethylamine (0.085 mL, 0.489 mmol) dissolved in N,N-dimethylformamide (2 mL) was stirred at 0 °C for 1 hour and further stirred at room temperature for 18 hours. An aqueous solution of N-ammonium chloride was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, water was removed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified and concentrated by column chromatography (SiO2, 10 g cartridge; ethyl acetate / hexane = 0% to 70%) to obtain the title compound (0.301 g, 69.5%) as a white solid. LRMS (ES) m / z 1349.9 [M+Na]+.
[0374]
[0375] Step 5: Synthesis of (2S,3S,4S,5R,6S)-6-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecane-17-amido)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
[0376] (2S,3R,4S,5S,6S)-2-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecane-17-amido)phenoxy)-6-(methoxycarbonyl)tetrahydride-2H-pyran-3,4,5-triyl triacetate (0.312 g, 0.235 mmol), lithium hydroxide (LiOH, 0.017 g, 0.705 mmol) and tetramethylammonium A solution of hydroxide (25.00% solution, 0.170 mL, 0.470 mmol) dissolved in 2-propanol (9 mL), tetrahydrofuran (3 mL), and water (4 mL) was stirred at -40 °C for 10 minutes and further stirred at -10 °C for 1 hour. Subsequently, acetic acid (0.067 mL, 1.175 mmol) was added to the reaction mixture at -10 °C and stirred for 10 minutes to terminate the reaction. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified by column chromatography (C18, 10 g cartridge; acetonitrile / 0.1% aqueous formic acid = 0% to 70%) and freeze-dried to obtain the title compound as a milky white solid. LRMS (ES) m / z 1186.4 [MH]-.
[0377]
[0378] Step 6: Synthesis of (2S,3S,4S,5R,6S)-6-(2-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propamido)-4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
[0379] (2S,3S,4S,5R,6S)-6-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecane-17-amido)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (0.238 g, 0.200 mmol) and hydrochloric acid (4.0 M 1,4-dioxane solution, 1.000 mL, 4.000 mmol) at 0 °C The solution dissolved in dichloromethane (1 mL) was stirred at the same temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified by column chromatography (Waters, C18; acetonitrile / 0.1%-20% to 50% aqueous formic acid) and freeze-dried to obtain the title compound (0.022 g, 10.1%) as a pale yellow solid. LRMS (ES) m / z 1086.3 [MH]-.
[0380]
[0381] Step 7: Synthesis of (2S,3S,4S,5R,6S)-6-(4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)-2-(1-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-3-oxo-7,10,13-trioxa-4-azhexadecane-16-amido)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
[0382] (2S,3S,4S,5R,6S)-6-(2-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propamido)-4-(10-(2-chloro-4-(3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-4-methyl-3-oxo-2,5,8-trioxa-4-azadecyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid(0.022 g, 0.020 mmol), 2,5-dioxopyrrolidine-1-yl A solution of 3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)propanoate (0.006 g, 0.024 mmol) and N,N-diisopropylethylamine (0.007 mL, 0.040 mmol) dissolved in N,N-dimethylformamide (1 mL) at room temperature was stirred at the same temperature for 1 hour. The reaction mixture was purified and concentrated by column chromatography (Waters, C18; acetonitrile / 0.1%-20% to 50% aqueous formic acid) to obtain the title compound (0.008 g, 31.9%) as a white solid. LRMS (ES) m / z 1239.4 [M+H]+.
[0383]
[0384] Example 41: Synthesis of LP6
[0385] LP6 was synthesized using a method similar to LP1.
[0386] LRMS (ES) m / z 1148.4 [M+H]+.
[0387]
[0388] Example 42: Synthesis of LP7
[0389] LP7 was synthesized using a method similar to that of LP5.
[0390] 1H NMR (400 MHz, DMSO-d6)δ 10.98 (s, 1H), 8.52 - 8.38 (m, 1H), 7.88 - 7.77 (m, 2H), 7.76 - 7.64 (m, 2H), 7.62 - 7.57 (m, 1H), 7.55 - 7.44 (m, 2H), 7.43 - 7.31 (m, 1H), 7.18 (br, 1H), 7.12 - 7.03 (m, 1H), 7.03 - 6.98 (m, 2H), 5.66 (br, 1H), 5.31 (br, 1H), 5.19 - 5.04 (m, 4H), 4.92 (t, J = 7.1 Hz, 1H), 4.39 (dd, J = 58.1, 16.9 Hz, 1H), 3.94 - 3.84 (m, 2H), 3.68 (s, 2H), 3.61 - 3.35 (m, 22H), 3.17 (q, J = 5.6 Hz, 2H), 3.05 - 3.01 (m, 2H), 2.99 - 2.86 (m, 1H), 2.68 (ddd, J = 7.6, 3.7, 1.9 Hz, 1H), 2.64 - 2.57 (m, 1H), 2.46 - 2.37 (m, 2H), 2.34 (dt, J = 3.5, 1.8 Hz, 2H), 2.12 - 1.97 (m, 4H), 1.52 - 1.39 (m, 6H), 1.35 (d, J = 9.8 Hz, 6H), 1.25 (s, 1H), 1.24 - 1.12 (m, 2H); LRMS (ES) m / z 1345.6 [M+Na]+.
[0391]
[0392] Example 43: Synthesis of LP8
[0393] LP8 was synthesized in a similar way to LP5.
[0394] 1H NMR (400 MHz, DMSO-d6)δ 10.98 (s, 1H), 8.38 (br, 1H), 8.01 (t, J = 5.6 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.69 (dd, J = 7.7, 1.8 Hz, 1H), 7.63 (s, 1H), 7.56 (s, 1H), 7.52 - 7.44 (m, 2H), 7.31 (d, J = 8.1 Hz, 1H), 7.25 - 7.17 (m, 1H), 7.12 - 7.04 (m, 1H), 7.03 - 6.97 (m, 2H), 5.68 (d, J = 4.1 Hz, 1H), 5.33 (br, 1H), 5.16 - 5.05 (m, 4H), 4.91 (t, J = 6.8 Hz, 1H), 4.39 (dd, J = 56.6, 17.3 Hz, 1H), 3.93 - 3.85 (m, 2H), 3.67 (s, 1H), 3.60 (t, J = 7.3 Hz, 1H), 3.56 - 3.41 (m, 29H), 3.39 - 3.35 (m, 4H), 3.19 - 3.11 (m, 3H), 3.01 (s, 3H), 2.97 - 2.84 (m, 1H), 2.71 - 2.55 (m, 1H), 2.46 - 2.36 (m, 2H), 2.36 - 2.30 (m, 3H), 2.03 - 1.95 (m, 1H), 1.41 (d, J = 6.9 Hz, 3H), 1.35 (d, J = 4.7 Hz, 6H); LRMS (ES) m / z 707.3 [M+2H]2+.
[0395]
[0396] Example 44: Synthesis of LP9
[0397] LP9 was synthesized in a similar way to LP1.
[0398] 1H NMR (400 MHz, DMSO-d6)δ 10.92 (s, 1H), 9.99 (s, 1H), 8.51 (t, J = 5.6 Hz, 1H), 7.91 (t, J = 11.2 Hz, 1H), 7.79 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.47 (s, 1H), 7.37 (t, J = 8.7 Hz, 1H), 7.18 - 7.09 (m, 2H), 6.94 (s, 2H), 6.90 (dd, J = 8.2, 2.1 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 5.63 (d, J = 3.8 Hz, 1H), 5.29 (td, J = 4.5, 2.2 Hz, 3H), 5.15 (s, 1H), 5.09 - 4.99 (m, 1H), 4.92 (d, J = 6.9 Hz, 1H), 4.42 - 4.29 (m, 1H), 4.28 - 4.19 (m, 1H), 3.82 (ddd, J = 44.7, 14.1, 7.0 Hz, 2H), 3.58 - 3.47 (m, 1H), 3.47 - 3.36 (m, 13H), 3.21 - 3.13 (m, 1H), 2.92 - 2.78 (m, 1H), 2.66 - 2.59 (m, 1H), 2.57 - 2.51 (m, 1H), 2.40 - 2.30 (m, 1H), 2.29 (t, J = 1.9 Hz, 1H), 1.98 - 1.93 (m, 8H); LRMS (ES) m / z 1149.4 [M+H]+.
[0399]
[0400] Example 45: Synthesis of LP10
[0401] LP10 was synthesized in a similar way to LP3.
[0402] 1H NMR (400 MHz, DMSO-d6)δ 10.98 (s,1H), 8.39 (d, J = 5.6 Hz, 1H), 7.88 (br, 1H), 7.84 - 7.78 (m, 1H), 7.72 - 7.67 (m, 1H), 7.64 (br, 1H), 7.57 (s, 1H), 7.52 - 7.43 (m, 2H), 7.37 - 7.29 (m, J = 7.7 Hz, 1H), 7.24 - 7.16 (m, 1H), 7.09 (d, J = 8.6 Hz, 1H), 7.01 - 6.97 (m, 2H), 5.76 (dd, J = 4.5, 2.0 Hz, 1H), 5.31 (br, 1H), 5.16 - 5.03 (m, 4H), 4.96 - 4.83 (m, 1H), 4.39 (dd, J = 56.7, 17.2 Hz, 1H), 3.93 - 3.84 (m, 2H), 3.68 (s, 2H), 3.58 - 3.48 (m, 2H), 3.42 - 3.35 (m, 4H), 3.26 - 3.15 (m, 2H), 3.02 (s, 3H), 2.97 - 2.86 (m, 1H), 2.71 - 2.56 (m, 1H), 2.44 - 2.35 (m, 2H), 2.34 (dt, J = 3.7, 1.8 Hz, 1H), 2.10 - 1.97 (m, 4H), 1.52 - 1.39 (m, 6H), 1.35 (d, J = 5.3 Hz, 6H), 1.25 (s, 1H), 1.22 - 1.12 (m, 2H); LRMS (ES) m / z 1213.4 [M+Na]+
[0403]
[0404] Example 46: Synthesis of LP11
[0405] LP11 was synthesized in a similar way to LP3.
[0406] 1H NMR (400 MHz, DMSO-d6)δ 10.99 (s, 1H), 10.49 (br, 1H), 8.35 (br, 1H), 7.88 (s, 1H), 7.80 (s, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.56 (s, 1H), 7.54 - 7.42 (m, 3H), 7.41 - 7.27 (m, 3H), 7.00 (s, 2H), 5.77 (s, 1H), 5.33 (s, 2H), 5.20 - 5.04 (m, 4H), 4.95 - 4.79 (m, 4H), 4.40 (dd, J = 55.6, 17.2 Hz, 2H), 3.90 (br, 1H), 3.26 - 3.16 (m, 2H), 3.00 - 2.84 (m, 2H), 2.69 - 2.62 (m, 2H), 2.43 - 2.33 (m, 3H), 2.12 - 2.04 (m, 5H), 1.57 - 1.37 (m, 6H), 1.23 - 1.11 (m, 3H); LRMS (ES) m / z 1115.4 [M+Na]+.
[0407]
[0408] Example 47: Synthesis of LP12
[0409] LP12 was synthesized in a similar way to LP1.
[0410] LRMS (ES) m / z 1119.5 [M+H]+.
[0411]
[0412] Example 48: Synthesis of LP13
[0413] LP13 was synthesized in a similar way to LP1.
[0414] LRMS (ES) m / z 1177.5 [M+H]+.
[0415]
[0416] Example 49: Synthesis of LP14
[0417] LP14 was synthesized in a similar way to LP1.
[0418] 1H NMR (400 MHz, DMSO-d6)δ 10.93 (s, 1H), 8.43 - 8.32 (m, 1H), 7.86 (t, J = 5.6 Hz, 1H), 7.75 (d, J = 2.1 Hz, 2H), 7.63 (d, J = 7.8 Hz, 1H), 7.47 (s, 1H), 7.40 (td, J = 7.2, 5.9, 1.8 Hz, 2H), 7.33 (d, J = 8.5 Hz, 1H), 7.17 - 7.06 (m, 1H), 6.94 (s, 2H), 6.81 - 6.72 (m, 1H), 5.04 (qd, J = 13.2, 7.4 Hz, 4H), 4.44 - 4.23 (m, 4H), 3.58 - 3.48 (m, 7H), 3.38 - 3.31 (m, 3H), 3.21 - 3.12 (m, 1H), 2.86 (ddd, J = 17.3, 13.3, 5.5 Hz, 1H), 2.61 (t, J = 7.3 Hz, 3H), 2.40 - 2.26 (m, 1H), 2.18 - 2.12 (m, 1H), 2.04 - 1.92 (m, 3H), 1.65 - 1.54 (m, 2H), 1.48 - 1.40 (m, 6H), 1.29 - 1.11 (m, 8H).; LRMS (ES) m / z 1149.5 [M+H]+.
[0419]
[0420] Example 50: Synthesis of LP15
[0421] A white solid compound, LP15 (0.006 g), was synthesized using a commercially available maleimide-glycine-glycine-phenylalanine-glycine-glycolic acid linker and P6. LRMS (ES) m / z 1184.7 [M+H]+.
[0422]
[0423] Example 51: Synthesis of LP16
[0424] A white solid compound, LP16 (0.005 g), was synthesized using a commercially available maleimide-glycine-glycine-phenylalanine-glycine-p-aminobenzoyl-p-nitrophenol linker and P6. LRMS (ES) m / z 1246.8 [M+H]+.
[0425]
[0426] Examples 52–74: Synthesis of LP17–LP39
[0427] It was synthesized using a method similar to the synthesis method of LP1.
[0428] 실시예1H-NMR (400 MHz, DMSO-d6), LRMS (ES)52δ 10.97 (s, 1H), 10.65 (s, 1H), 8.82 (s, 1H), 8.30 (d, J = 6.0 Hz, 1H), 8.01 (d, J = 7.1 Hz, 1H), 7.86 (d, J = 5.2 Hz, 1H), 7.78 (d, J = 2.3 Hz, 1H), 7.73 - 7.61 (m, 2H), 7.55 (s, 1H), 7.52 - 7.42 (m, 2H), 7.28 (d, J = 8.5 Hz, 1H), 7.16 - 7.04 (m, 2H), 6.98 (d, J = 1.5 Hz, 2H), 5.77 (q, J = 3.7 Hz, 1H), 5.34 (s, 1H), 5.09 (d, J = 11.8 Hz, 4H), 4.89 (p, J = 7.1 Hz, 1H), 4.50 - 4.25 (m, 2H), 4.14 (s, 2H), 3.90 (d, J = 9.2 Hz, 1H), 3.35 (t, J = 2.5 Hz, 13H), 2.90 (ddd, J = 17.9, 13.6, 5.4 Hz, 1H), 2.74 (t, J = 7.2 Hz, 2H), 2.67 - 2.54 (m, 1H), 2.45 - 2.31 (m, 1H), 2.10 - 1.94 (m, 3H), 1.52 - 1.36 (m, 7H), 1.27 - 1.11 (m, 2H); LRMS (ES) m / z 1162.4 [M+H]+53LRMS (ES) m / z 1091.3 [M+H]+54δ 11.11 (d, J = 4.3 Hz, 1H), 10.94 (s, 1H), 8.32 (q, J = 5.7 Hz, 1H), 7.86 (t, J = 5.6 Hz, 1H), 7.79 - 7.69 (m, 2H), 7.65 (dd, J = 7.6, 2.7 Hz, 1H), 7.47 (s, 1H), 7.41 (td, J = 8.4, 7.8, 1.8 Hz, 2H), 7.34 - 7.30 (m, 1H), 7.25 (d, J = 8.4 Hz, 1H), 7.11 (dt, J = 8.4, 2.3 Hz, 1H), 6.95 (d, J = 1.4 Hz, 2H), 5.75 - 5.69 (m, 1H), 5.28 (d, J = 5.2 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.97 (d, J = 4.0 Hz, 2H), 4.44 - 4.23 (m, 4H), 3.93 - 3.75 (m, 3H), 3.51 - 3.45 (m, 2H), 3.31 (s, 9H), 3.23 - 3.10 (m, 1H), 2.92 - 2.79 (m, 3H), 2.64 - 2.49 (m, 1H), 2.40 - 2.27 (m, 1H), 2.04 - 1.91 (m, 3H), 1.42 (h, J = 7.2 Hz, 4H), 1.20 (d, J = 6.9 Hz, 2H), 1.12 (td, J = 8.3, 7.6, 2.9 Hz, 2H); LRMS (ES) m / z 1148.4 [M+H]+55δ 10.99 (s, 1H), 10.42 (s, 1H), 9.33 (s, 1H), 8.37 (t, J = 6.0 Hz, 1H), 7.90 (t, J = 5.7 Hz, 1H), 7.78 (dd, J = 6.4, 2.2 Hz, 2H), 7.68 (d, J = 7.8 Hz, 1H), 7.51 (s, 1H), 7.47 - 7.40 (m, 2H), 7.28 (d, J = 8.6 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 6.98 (s, 2H), 5.77 (d, J = 4.1 Hz, 1H), 5.34 (d, J = 4.1 Hz, 1H), 5.14 - 5.01 (m, 4H), 4.76 (s, 2H), 4.48 - 4.27 (m, 4H), 3.91 - 3.84 (m, 1H), 3.55 - 3.12 (m, 11H), 2.90 (ddd, J = 17.3, 13.6, 5.4 Hz, 1H), 2.61 (tdd, J = 17.3, 4.2, 2.0 Hz, 1H), 2.45 - 2.32 (m, 1H), 2.08 - 1.95 (m, 3H), 1.44 (h, J = 7.5 Hz, 4H), 1.25 - 1.09 (m, 2H); LRMS (ES) m / z 1077.5 [M+H]+561H NMR (400 MHz, DMSO-d6)δ 11.01 (s, 1H), 10.94 (s, 1H), 8.29 (t, J = 5.7 Hz, 1H), 8.10 (d, J = 6.3 Hz, 1H), 7.84 (d, J = 6.0 Hz, 1H), 7.75 (dd, J = 12.0, 2.3 Hz, 1H), 7.65 (dd, J = 7.9, 2.4 Hz, 2H), 7.47 (s, 1H), 7.44 - 7.38 (m, 3H), 7.24 (t, J = 8.6 Hz, 2H), 7.12 (dd, J = 8.3, 2.3 Hz, 1H), 6.95 (s, 2H), 5.72 (d, J = 4.2 Hz, 1H), 5.28 (q, J = 4.6, 4.0 Hz, 1H), 5.11 - 5.01 (m, 2H), 4.96 (s, 2H), 4.47 - 4.22 (m, 4H), 3.88 (t, J = 6.7 Hz, 2H), 3.82 (dd, J = 10.0, 4.3 Hz, 1H), 3.60 (t, J = 4.9 Hz, 4H), 3.17 (dt, J = 9.6, 6.3 Hz, 1H), 2.87 (tdd, J = 14.0, 8.8, 5.4 Hz, 3H), 2.64 - 2.50 (m, 2H), 2.41 - 2.26 (m, 1H), 2.07 - 1.88 (m, 4H), 1.42 (h, J = 7.5 Hz, 5H), 1.30 - 0.99 (m, 8H); LRMS (ES) m / z 1205.3 [M+H]+57LRMS (ES) m / z 1203.5 [M-H]-58δ 10.92 (s, 1H), 10.64 (s, 1H), 8.33 (s, 1H), 7.85 - 7.81 (m, 1H), 7.78 - 7.74 (m, 1H), 7.64 (td, J = 5.6, 4.9, 3.0 Hz, 2H), 7.56 (dd, J = 4.6, 2.4 Hz, 1H), 7.51 (d, J = 2.7 Hz, 1H), 7.44 (dd, J = 9.2, 2.3 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.13 (dd, J = 8.8, 4.8 Hz, 1H), 7.01 (dt, J = 9.1, 2.4 Hz, 1H), 6.94 (d, J = 0.8 Hz, 2H), 5.70 (d, J = 4.1 Hz, 1H), 5.25 (s, 1H), 5.09 - 5.00 (m, 4H), 4.86 (t, J = 7.1 Hz, 1H), 4.40 (d, J = 17.2 Hz, 1H), 4.26 (dd, J = 17.4, 3.4 Hz, 1H), 4.10 (d, J = 11.9 Hz, 2H), 3.68 - 3.43 (m, 3H), 3.32 (d, J = 13.3 Hz, 3H), 3.17 (ddt, J = 19.3, 13.0, 7.4 Hz, 6H), 2.93 - 2.79 (m, 1H), 2.64 - 2.51 (m, 1H), 2.41 - 2.26 (m, 1H), 2.05 - 1.90 (m, 4H), 1.39 (dt, J = 21.1, 7.1 Hz, 7H), 1.31 (d, J = 3.1 Hz, 6H), 1.12 (tt, J = 10.0, 6.5 Hz, 2H); LRMS (ES) m / z 1190.4 [M+H]+59δ 10.92 (s, 1H), 8.36 (d, J = 5.8 Hz, 1H), 7.85 (t, J = 5.6 Hz, 1H), 7.79 - 7.71 (m, 2H), 7.66 - 7.61 (m, 1H), 7.47 (s, 1H), 7.40 (ddd, J = 7.7, 5.4, 1.8 Hz, 2H), 7.32 (dd, J = 11.3, 8.6 Hz, 1H), 7.12 - 7.03 (m, 2H), 6.94 (d, J = 1.2 Hz, 2H), 5.67 (d, J = 3.6 Hz, 1H), 5.38 - 5.33 (m, 1H), 5.21 (s, 1H), 5.08 (s, 2H), 5.07 - 5.03 (m, 1H), 4.98 (d, J = 6.1 Hz, 1H), 4.44 - 4.23 (m, 4H), 3.99 (qd, J = 7.1, 3.1 Hz, 2H), 3.87 (t, J = 4.7 Hz, 2H), 3.66 (t, J = 6.9 Hz, 2H), 3.56 - 3.48 (m, 4H), 3.35 - 3.29 (m, 7H), 3.22 - 3.10 (m, 1H), 2.92 - 2.80 (m, 1H), 2.78 (t, J = 6.5 Hz, 2H), 2.65 - 2.53 (m, 1H), 2.50 (t, J = 6.8 Hz, 2H), 2.41 - 2.27 (m, 1H), 2.04 - 1.92 (m, 3H), 1.41 (hept, J = 6.7, 6.1 Hz, 4H), 1.20 (d, J = 3.1 Hz, 2H), 1.10 (td, J = 7.1, 1.9 Hz, 5H); LRMS (ES) m / z 1235.4 [M+H]+.60δ 10.91 (s, 1H), 9.92 (s, 1H), 8.44 (t, J = 5.7 Hz, 1H), 7.97 - 7.86 (m, 2H), 7.77 (dd, J = 10.9, 1.9 Hz, 2H), 7.62 (d, J = 7.9 Hz, 1H), 7.47 (s, 1H), 7.42 - 7.33 (m, 3H), 7.08 - 7.00 (m, 1H), 6.93 (s, 2H), 5.63 (s, 1H), 5.18 - 5.01 (m, 3H), 4.96 - 4.90 (m, 1H), 4.45 - 4.23 (m, 4H), 3.87 (q, J = 5.9, 5.0 Hz, 2H), 3.63 (t, J = 7.0 Hz, 2H), 3.58 - 3.45 (m, 2H), 3.24 - 3.13 (m, 10H), 2.93 - 2.72 (m, 3H), 2.61 - 2.49 (m, 1H), 2.43 - 2.27 (m, 2H), 2.03 - 1.92 (m, 4H), 1.46 - 1.37 (m, 4H), 1.20 (d, J = 3.4 Hz, 5H), 1.16 - 1.06 (m, 2H); LRMS (ES) m / z 1205.3 [M-H]-61δ 11.23 (s, 1H), 10.94 (s, 1H), 10.62 (s, 1H), 8.43 (t, J = 6.0 Hz, 1H), 8.12 (s, 1H), 7.91 - 7.86 (m, 1H), 7.75 (s, 1H), 7.66 - 7.61 (m, 2H), 7.49 - 7.38 (m, 3H), 7.25 (d, J = 18.6 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 6.94 (d, J = 1.4 Hz, 2H), 5.03 (s, 2H), 4.44 - 4.22 (m, 4H), 3.93 - 3.76 (m, 2H), 3.60 - 3.45 (m, 2H), 3.24 - 3.11 (m, 15H), 2.86 (tq, J = 11.2, 5.2 Hz, 3H), 2.68 - 2.52 (m, 1H), 2.37 - 2.26 (m, 1H), 1.97 (q, J = 12.5, 10.0 Hz, 3H), 1.41 (q, J = 7.3 Hz, 3H), 1.20 - 1.06 (m, 3H); LRMS (ES) m / z 1162.3 [M-H]-62δ 10.99 (s, 1H), 10.70 (s, 1H), 9.09 (s, 1H), 8.34 (t, J = 5.7 Hz, 1H), 8.20 (dt, J = 12.0, 5.8 Hz, 2H), 7.96 - 7.86 (m, 2H), 7.78 (d, J = 2.3 Hz, 1H), 7.68 (dd, J = 5.0, 2.9 Hz, 2H), 7.55 - 7.40 (m, 3H), 7.27 (d, J = 8.6 Hz, 1H), 7.19 - 7.09 (m, 2H), 6.98 (d, J = 1.7 Hz, 2H), 5.78 (d, J = 4.0 Hz, 1H), 5.34 (d, J = 3.9 Hz, 1H), 5.14 - 5.05 (m, 4H), 4.51 - 4.23 (m, 6H), 3.91 - 3.82 (m, 1H), 3.78 (d, J = 5.6 Hz, 2H), 3.64 (d, J = 5.6 Hz, 2H), 3.38 (s, 13H), 2.90 (ddd, J = 17.3, 13.6, 5.4 Hz, 1H), 2.73 (t, J = 7.3 Hz, 2H), 2.59 (ddd, J = 17.4, 4.4, 2.2 Hz, 1H), 2.38 (qd, J = 13.1, 4.4 Hz, 1H), 2.13 - 1.94 (m, 3H), 1.45 (h, J = 7.5 Hz, 4H), 1.26 - 1.06 (m, 2H); LRMS (ES) m / z 1262.3 [M+H]+63δ 10.98 (s, 1H), 10.42 (s, 1H), 9.01 (s, 1H), 8.34 (t, J = 5.7 Hz, 1H), 7.88 (t, J = 5.7 Hz, 1H), 7.83 - 7.65 (m, 3H), 7.56 (s, 1H), 7.55 - 7.38 (m, 2H), 7.26 (dd, J = 16.6, 8.5 Hz, 2H), 7.11 (t, J = 7.5 Hz, 1H), 6.98 (s, 2H), 5.78 (d, J = 4.3 Hz, 1H), 5.34 (d, J = 4.2 Hz, 1H), 5.19 - 5.00 (m, 4H), 4.90 (p, J = 7.0 Hz, 1H), 4.75 (s, 2H), 4.37 (ddd, J = 55.6, 17.4, 3.2 Hz, 2H), 3.91 (d, J = 9.2 Hz, 1H), 3.36 (s, 11H), 2.91 (ddd, J = 17.2, 13.6, 5.4 Hz, 1H), 2.70 - 2.51 (m, 2H), 2.47 - 2.30 (m, 1H), 2.03 (tt, J = 15.1, 6.8 Hz, 3H), 1.44 (dt, J = 13.4, 7.2 Hz, 7H), 1.26 - 1.07 (m, 2H); LRMS (ES) m / z 1091.3 [M+H]+64δ 10.93 (s, 1H), 9.04 (s, 1H), 8.15 (d, J = 2.1 Hz, 1H), 7.83 (s, 1H), 7.69 - 7.60 (m, 2H), 7.47 (s, 1H), 7.40 (dd, J = 7.9, 1.4 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 7.13 - 7.02 (m, 2H), 6.99 (dd, J = 8.4, 2.1 Hz, 1H), 6.94 (s, 2H), 5.77 (d, J = 4.1 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 5.00 (s, 2H), 4.78 (d, J = 7.3 Hz, 1H), 4.44 - 4.22 (m, 4H), 3.89 (dd, J = 5.7, 3.5 Hz, 2H), 3.56 - 3.50 (m, 4H), 3.34 (d, J = 12.8 Hz, 5H), 2.92 - 2.82 (m, 1H), 2.79 (t, J = 6.9 Hz, 2H), 2.63 - 2.50 (m, 3H), 2.41 - 2.27 (m, 1H), 1.98 (q, J = 10.5, 8.9 Hz, 4H), 1.42 (q, J = 7.3 Hz, 4H), 1.20 (s, 4H), 1.17 - 1.06 (m, 2H); LRMS (ES) m / z 1132.4 [M+H]+65δ 10.91 (s, 1H), 10.38 (s, 1H), 8.27 (t, J = 5.7 Hz, 1H), 7.80 (t, J = 5.6 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.65 (dd, J = 7.9, 1.5 Hz, 1H), 7.62 (d, J = 2.1 Hz, 1H), 7.52 (s, 1H), 7.47 - 7.40 (m, 2H), 7.25 (d, J = 8.5 Hz, 1H), 7.14 (dd, J = 8.4, 1.3 Hz, 1H), 7.04 (dd, J = 8.4, 2.2 Hz, 1H), 6.94 (s, 2H), 5.69 (d, J = 4.4 Hz, 1H), 5.25 (d, J = 4.3 Hz, 1H), 5.09 - 5.00 (m, 4H), 4.87 (t, J = 7.1 Hz, 1H), 4.45 - 4.24 (m, 2H), 3.85 (d, J = 9.2 Hz, 1H), 3.79 (dd, J = 5.5, 3.8 Hz, 2H), 3.55 - 3.49 (m, 4H), 3.41 - 3.15 (m, 7H), 2.86 (ddd, J = 13.7, 12.3, 6.8 Hz, 1H), 2.78 (t, J = 7.0 Hz, 2H), 2.65 - 2.53 (m, 1H), 2.42 - 2.28 (m, 1H), 2.00 (t, J = 7.2 Hz, 2H), 1.97 - 1.92 (m, 1H), 1.43 (dt, J = 15.9, 7.9 Hz, 5H), 1.39 - 1.36 (m, 3H), 1.17 - 1.09 (m, 2H); LRMS (ES) m / z 1149.4 [M+H]+66δ 10.91 (s, 1H), 10.30 (s, 1H), 8.42 (s, 1H), 7.87 (d, J = 4.4 Hz, 1H), 7.73 - 7.69 (m, 2H), 7.63 (dd, J = 7.9, 1.9 Hz, 2H), 7.53 (d, J = 6.4 Hz, 1H), 7.45 (ddd, J = 8.0, 4.5, 1.4 Hz, 1H), 7.35 (s, 2H), 7.11 (dd, J = 8.4, 3.6 Hz, 1H), 6.93 (s, 2H), 6.47 (s, 1H), 5.65 (s, 1H), 5.17 (s, 1H), 5.09 - 4.96 (m, 4H), 4.86 (t, J = 7.1 Hz, 1H), 4.40 (dd, J = 17.3, 3.4 Hz, 1H), 4.32 - 4.20 (m, 1H), 3.97 - 3.79 (m, 2H), 3.65 (d, J = 7.9 Hz, 1H), 3.41 (d, J = 15.2 Hz, 1H), 3.30 - 3.11 (m, 7H), 2.85 (ddt, J = 20.8, 12.3, 6.2 Hz, 3H), 2.67 - 2.50 (m, 1H), 2.41 - 2.27 (m, 1H), 2.07 - 1.91 (m, 3H), 1.47 - 1.34 (m, 7H), 1.20 - 1.04 (m, 3H); LRMS (ES) m / z 1103.4 [M-H]-67δ 10.91 (s, 1H), 9.42 (s, 1H), 8.30 (t, J = 5.8 Hz, 1H), 7.81 (t, J = 5.6 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.68 (d, J = 1.9 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.47 (s, 1H), 7.41 (ddd, J = 9.4, 8.2, 1.9 Hz, 2H), 7.26 (d, J = 8.6 Hz, 1H), 7.09 - 7.05 (m, 2H), 6.94 (s, 2H), 5.68 (d, J = 4.2 Hz, 1H), 5.08 - 5.01 (m, 4H), 4.43 - 4.24 (m, 4H), 3.54 - 3.47 (m, 6H), 3.38 - 3.28 (m, 11H), 3.22 - 3.12 (m, 1H), 2.87 (ddd, J = 17.3, 13.5, 5.4 Hz, 1H), 2.77 (t, J = 6.8 Hz, 2H), 2.63 - 2.51 (m, 1H), 2.41 - 2.29 (m, 1H), 2.04 - 1.93 (m, 3H), 1.42 (hept, J = 6.7, 6.2 Hz, 4H), 1.17 - 1.08 (m, 2H); LRMS (ES) m / z 1135.4 [M+H]+68δ 10.98 (s, 1H), 10.65 (s, 1H), 9.00 (s, 1H), 8.35 (dt, J = 16.8, 5.7 Hz, 1H), 8.02 (dt, J = 17.7, 5.7 Hz, 1H), 7.87 (td, J = 5.7, 1.9 Hz, 1H), 7.85 - 7.78 (m, 1H), 7.75 - 7.62 (m, 2H), 7.52 (s, 1H), 7.45 (dt, J = 7.9, 2.3 Hz, 2H), 7.31 (dd, J = 8.6, 3.1 Hz, 1H), 7.14 - 7.05 (m, 2H), 6.98 (s, 2H), 5.82 - 5.72 (m, 1H), 5.33 (s, 1H), 5.15 - 5.05 (m, 4H), 4.69 (q, J = 7.3 Hz, 1H), 4.52 - 4.27 (m, 2H), 4.15 (d, J = 7.1 Hz, 2H), 3.96 - 3.81 (m, 1H), 3.36 (s, 13H), 2.90 (ddd, J = 17.2, 13.6, 5.4 Hz, 1H), 2.75 (t, J = 7.0 Hz, 2H), 2.68 - 2.56 (m, 1H), 2.47 - 2.32 (m, 1H), 2.03 (td, J = 13.9, 13.3, 7.8 Hz, 3H), 1.82 - 1.68 (m, 2H), 1.45 (h, J = 7.3 Hz, 4H), 1.24 - 1.13 (m, 3H), 0.86 (t, J = 7.3 Hz, 3H); LRMS (ES) m / z 1176.6 [M+H]+69δ 11.20 (s, 1H), 10.98 (s, 1H), 8.85 (s, 1H), 8.32 (t, J = 5.7 Hz, 1H), 7.86 (t, J = 5.7 Hz, 1H), 7.80 - 7.74 (m, 1H), 7.72 - 7.63 (m, 2H), 7.55 (s, 1H), 7.52 - 7.43 (m, 2H), 7.29 (dd, J = 15.2, 8.4 Hz, 2H), 7.17 - 7.08 (m, 1H), 6.98 (s, 2H), 5.77 (d, J = 4.0 Hz, 1H), 5.34 (d, J = 4.3 Hz, 1H), 5.19 - 4.96 (m, 4H), 4.90 (p, J = 7.0 Hz, 1H), 4.50 - 4.24 (m, 2H), 4.09 - 3.81 (m, 7H), 3.55 - 3.08 (m, 13H), 2.95 - 2.82 (m, 3H), 2.66 - 2.55 (m, 1H), 2.46 - 2.29 (m, 1H), 2.09 - 1.93 (m, 3H), 1.51 - 1.35 (m, 7H), 1.24 - 1.09 (m, 2H); LRMS (ES) m / z 1188.4 [M+H]70δ 11.02 (s, 1H), 10.94 (s, 1H), 8.83 (s, 1H), 8.58 - 8.47 (m, 1H), 8.22 (s, 2H), 7.65 (d, J = 7.8 Hz, 1H), 7.60 (t, J = 3.4 Hz, 1H), 7.54 (d, J = 2.3 Hz, 1H), 7.52 (s, 1H), 7.43 (dd, J = 13.7, 8.2 Hz, 2H), 7.30 - 7.14 (m, 1H), 7.14 - 7.01 (m, 1H), 6.94 (s, 2H), 5.32 - 4.75 (m, 3H), 4.46 - 4.19 (m, 2H), 3.88 (t, J = 7.0 Hz, 2H), 3.78 (s, 1H), 3.35 (s, 6H), 2.85 (t, J = 6.8 Hz, 3H), 2.67 - 2.55 (m, 5H), 2.43 - 2.26 (m, 1H), 2.07 - 1.78 (m, 3H), 1.37 (d, J = 7.2 Hz, 3H), 1.19 (s, 4H), 0.97 (t, J = 7.1 Hz, 8H); LRMS (ES) m / z 1176.2 [M-H]-71δ 10.91 (s, 1H), 10.64 (s, 1H), 8.33 (t, J = 5.6 Hz, 1H), 7.83 (t, J = 5.6 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.68 (d, J = 2.3 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.46 (s, 1H), 7.40 (td, J = 8.7, 1.9 Hz, 2H), 7.27 (d, J = 8.6 Hz, 1H), 7.17 (d, J = 8.8 Hz, 1H), 7.07 (dd, J = 8.8, 2.4 Hz, 1H), 6.94 (s, 2H), 5.68 (d, J = 4.0 Hz, 1H), 5.23 (d, J = 3.9 Hz, 1H), 5.09 - 4.98 (m, 4H), 4.45 - 4.23 (m, 4H), 4.11 (d, J = 12.1 Hz, 2H), 3.84 - 3.75 (m, 1H), 3.69 - 3.42 (m, 2H), 3.32 (d, J = 8.2 Hz, 9H), 3.21 - 3.11 (m, 1H), 2.90 - 2.82 (m, 1H), 2.56 (ddd, J = 17.2, 4.6, 2.4 Hz, 1H), 2.39 - 2.27 (m, 1H), 2.04 - 1.91 (m, 3H), 1.47 - 1.37 (m, 4H), 1.32 (s, 6H), 1.22 - 1.19 (m, 1H), 1.18 - 1.08 (m, 2H); LRMS (ES) m / z 1174.2 [M-H]-72δ 10.93 (s, 1H), 8.49 - 8.43 (m, 1H), 7.89 (d, J = 5.2 Hz, 1H), 7.75 (s, 1H), 7.66 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 7.9, 2.3 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.44 (t, J = 6.7 Hz, 2H), 7.38 (s, 1H), 7.06 (d, J = 5.9 Hz, 1H), 7.02 (dt, J = 6.1, 2.7 Hz, 1H), 6.93 (s, 2H), 5.10 - 5.01 (m, 3H), 4.86 (d, J = 1.8 Hz, 1H), 4.41 (d, J = 17.3 Hz, 1H), 4.28 (d, J = 2.9 Hz, 1H), 3.97 (q, J = 7.1 Hz, 2H), 3.80 (d, J = 5.2 Hz, 2H), 3.61 (d, J = 6.2 Hz, 5H), 3.31 (s, 18H), 2.86 (ddd, J = 17.1, 13.5, 5.4 Hz, 1H), 2.65 - 2.52 (m, 1H), 2.40 - 2.26 (m, 1H), 1.97 (dt, J = 14.0, 6.9 Hz, 4H), 1.40 (q, J = 7.3 Hz, 4H), 1.30 (t, J = 13.8 Hz, 3H), 1.26 - 1.18 (m, 4H), 1.14 - 1.06 (m, 5H); LRMS (ES) m / z 1299.4 [M+Na]+73δ 10.99 (s, 1H), 9.21 (s, 1H), 8.37 (d, J = 5.9 Hz, 1H), 7.97 - 7.88 (m, 1H), 7.84 - 7.64 (m, 3H), 7.55 - 7.36 (m, 4H), 7.29 (dd, J = 8.6, 2.8 Hz, 1H), 7.14 (ddd, J = 21.3, 7.1, 2.6 Hz, 3H), 6.98 (d, J = 2.7 Hz, 2H), 5.77 (d, J = 3.8 Hz, 1H), 5.33 (s, 1H), 5.08 (dd, J = 15.6, 4.5 Hz, 4H), 4.54 - 4.25 (m, 4H), 4.07 - 3.81 (m, 5H), 3.38 (s, 15H), 2.98 - 2.75 (m, 3H), 2.69 - 2.55 (m, 1H), 2.38 (qt, J = 13.3, 3.6 Hz, 1H), 2.02 (tdd, J = 17.3, 6.3, 2.8 Hz, 3H), 1.44 (td, J = 8.6, 8.2, 3.9 Hz, 4H), 1.27 - 1.08 (m, 3H); LRMS (ES) m / z 1192.4 [M+H]+74δ 10.97 (s, 1H), 8.39 (s, 1H), 7.88 (dt, J = 5.7, 3.1 Hz, 1H), 7.78 (d, J = 2.3 Hz, 1H), 7.71 - 7.59 (m, 2H), 7.53 - 7.41 (m, 2H), 7.34 (d, J = 6.5 Hz, 2H), 7.18 (dd, J = 8.8, 3.4 Hz, 1H), 7.13 - 7.05 (m, 2H), 6.98 (s, 2H), 6.54 (s, 0H), 5.80 - 5.71 (m, 1H), 5.30 (s, 1H), 5.08 (tdd, J = 13.0, 6.1, 3.8 Hz, 4H), 4.89 (h, J = 6.2 Hz, 1H), 4.52 - 4.26 (m, 2H), 3.98 (s, 2H), 3.88 (t, J = 4.9 Hz, 2H), 3.81 (s, 1H), 3.64 (s, 2H), 3.36 (s, 11H), 2.90 (ddd, J = 17.2, 13.6, 5.4 Hz, 1H), 2.80 (s, 1H), 2.70 - 2.54 (m, 2H), 2.45 - 2.29 (m, 1H), 2.17 (t, J = 7.4 Hz, 0H), 2.10 - 1.95 (m, 3H), 1.65 - 1.57 (m, 1H), 1.52 - 1.38 (m, 7H), 1.32 (d, J = 6.5 Hz, 6H), 1.28 - 1.09 (m, 3H); LRMS (ES) m / z 1234.4 [M+H]+.
[0429]
[0430] Example 75: Synthesis of LP40
[0431]
[0432] LP40 was synthesized using a commercially available GGFG-PNP linker.
[0433] 2-amino-N-(2-((2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phennetoxy)amino)-2-oxoethyl)amino)-2-oxoethyl)acetamide (0.046 mmol, 0.046 mmol) and N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrole-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[(4-nitrophenoxy)carbonyl]oxy]methyl]phenyl]-L-onitinamide (3.394 g, 4.600 mmol) were dissolved in N,N-dimethylformamide (2 mL) and at 0 °C 1-hydroxybenzotriazole hydrate (0.009 g, 0.069 mmol) and N,N-diisopropylethylamine (0.002 mL, 0.009 mmol) were added and stirred for 10 minutes at the same temperature, followed by further stirring for 1 hour at room temperature. The reaction mixture was filtered through a plastic filter to remove the solid, and the filtrate was purified and concentrated by column chromatography (Waters, C18; acetonitrile / formic acid = 30% to 50%) to obtain compound LP40 (0.033 g, 56.8%) in the form of a white solid.
[0434] 1H NMR (400 MHz, DMSO-d6) δ 11.06 (s, 1H),1 0.95 (s, 1H), 9.97 (s,1 H), 8.92 (s,1 H), 8.15 - 8.01 (m,3 H), 7.78 (d,J = 8.7 Hz, 1H), 7.66 - 7.63 (m, 2H), 7.55 (d, J = 8.3 Hz, 2H), 7.47 (s, 1H), 7.43 - 7.37 (m, 2H), 7.25 (dd, J = 8.4, 6.2 Hz, 3H), 7.13 (dd, J = 8.4, 2.2 Hz, 1H), 6.96 (s, 2H), 6.94 (s, 1H), 5.95 (s, 1H), 5.38 (s, 2H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.91 (s, 2H), 4.45 - 4.23 (m, 4H), 4.14 (dd, J = 8.6, 6.8 Hz, 1H), 3.88 (t, J = 6.9 Hz, 2H), 3.70 (d, J = 5.7 Hz, 2H), 3.60 (t, J = 6.7 Hz, 4H), 3.03 - 2.93 (m, 1H), 2.89 - 2.80 (m, 4H), 2.65 - 2.51 (m, 1H), 2.40 - 2.26 (m, 1H), 2.17 - 2.02 (m, 1H), 1.98 - 1.87 (m, 2H), 1.71 - 1.49 (m, 1H), 1.43 (p, J = 7.2 Hz, 4H), 1.24 - 1.05 (m, 4H), 0.79 (dd, J = 13.2, 6.7 Hz, 6H); LRMS (ES) m / z 1255.4 [M+H]+.
[0435]
[0436] Example 76: Synthesis of LP41
[0437] LP41 was synthesized using a method similar to that of LP40.
[0438] 1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 9.98 (s, 1H), 8.79 (s, 1H), 8.06 (d,J = 7.5 Hz, 1H), 7.77 (d, J = 8.6 Hz, 1H), 7.65 (dd, J = 7.8, 0.7 Hz, 1H), 7.62 (d, J = 2.1 Hz, 1H), 7.60 - 7.52 (m, 2H), 7.47 (d, J = 1.4 Hz, 1H), 7.40 (dd, J = 7.9, 1.4 Hz, 1H), 7.31 - 7.22 (m, 2H), 7.15 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.4, 2.1 Hz, 1H), 6.95 (s, 2H), 6.81 (t, J = 6.0 Hz, 1H), 5.94 (s, 1H), 5.38 (s, 2H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 5.02 (s, 2H), 4.44 - 4.23 (m, 5H), 4.14 (dd, J = 8.6, 6.8 Hz, 1H), 3.98 (q, J = 7.1 Hz, 2H), 3.87 (dd, J = 5.8, 3.3 Hz, 2H), 3.65 (t, J = 6.8 Hz, 2H), 3.52 - 3.46 (m, 5H), 3.02 - 2.83 (m, 1H), 2.78 (t, J = 7.0 Hz, 2H), 2.51 (t, J = 6.9 Hz, 2H), 2.41 - 2.27 (m, 1H), 2.18 - 2.02 (m, 2H), 1.99 - 1.85 (m, 2H), 1.69 - 1.51 (m, 1H), 1.47 - 1.37 (m, 4H), 1.19 (s, 1H), 1.16 - 1.06 (m, 4H), 0.79 (dd, J = 12.8, 6.8 Hz, 6H); LRMS (ES) m / z 1228.5 [M+H]+.
[0439]
[0440] 실시예 77: LP43의 합성
[0441]
[0442] Step 1: Synthesis of LP43-1
[0443] 2-(3-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)propanamido)ethyl (N-(2-aminoethyl)sulfamoyl)carbamate was synthesized by the method known in Antibodies 2018, 7, 12. Synthesized sulfamide linker (0.044 g, 0.078 mmol), linker LP3-7 (0.075 g, 0.071 mmol), 1-[bis(dimethylmaminomethylene)-1-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 0.032 g, 0.085 mmol), and N,N-diasopropylethylamine (0.062 mL, 0.356 mmol) were dissolved in N,N-dimethylformamide (2 mL) at 0 °C and stirred at the same temperature for 1 hour. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (SiO2, 5 g cartridge; methanol / dichloromethane = 0% to 5%) to obtain LP43-1 (0.078 g, 73.6%) in solid form. LRMS (ES) m / z 1556.0 [M+H]+.
[0444]
[0445] Step 2: Synthesis of LP43-2
[0446] A solution of LP43-1 (0.078 g, 0.052 mmol) and lithium hydroxide (0.005 g, 0.209 mmol) dissolved in 2-propanol (4 mL), tetrahydrofuran (4 mL), and water (2 mL) was stirred at -20 °C for 10 minutes, followed by additional stirring at -10 °C for 1 hour, stirring for 1 minute, and then adding the reactant acetic acid at 0 °C and stirring for 5 minutes to terminate the reaction. After removing the solvent from the reaction mixture under reduced pressure, the concentrate was purified and concentrated by column chromatography (C18, 10 g cartridge; acetonitrile / formic acid = 0% to 80%) to obtain LP43-2 (0.023 g, 39.2%) as a white solid. LRMS (ES) m / z 1193.7 [M+H]+.
[0447]
[0448] Step 3: Synthesis of LP43-2
[0449] A solution of LP43-2 (0.023 g, 0.020 mmol), 2,5-dioxopyrrolidine-1-yl 3-(2,5-dioxo-2,5-dihydro-1-pyrrole-1-yl)propanoate (0.007 g, 0.028 mmol), and N,N-diisopropylethylamine (0.011 mL, 0.061 mmol) dissolved in NN-dimethylformamide (1 mL) at 0 °C was stirred at the same temperature for 30 minutes. The reaction mixture was purified and concentrated by column chromatography (Waters, C18; acetonitrile / 0.1%-formic acid aqueous solution 20% to 50%) to obtain LP43 (0.018 g, 70.5%). LRMS (ES) m / z 1344.8 [M+H]+.
[0450]
[0451] Example 78: Synthesis of LP44:
[0452] LP44 was synthesized in a similar way to LP43.
[0453] LRMS (ES) m / z 1406.1 [M+H]+.
[0454]
[0455] Example 79: Synthesis of LP45
[0456] LP45 was synthesized in a similar way to LP43.
[0457] LRMS (ES) m / z 1316.0 [M+H]+.
[0458]
[0459] Example 80: Synthesis of LP46
[0460] LP46 was synthesized in a similar way to LP43.
[0461] LRMS (ES) m / z 1405.9 [M+H]+.
[0462]
[0463] Synthesis of Antibody-Linker-Payload Conjugate (Anti-CD33-LP)
[0464] Examples 81–121
[0465] 4 mg / mL of CD33 antibody (prepared by the same method as described in Orom Therapeutics patent KR10-2024-0040067) was reacted with 4 molar of TCEP (Tris(2-caboxyethyl)phosphine hydrochloride) at 25°C for 2 hours to generate cysteine from disulfide bonds. The reduced CD33 antibody was purified from the unreacted TCEP using a PD-10 desalting column. 2 mg / mL of the reduced CD33 antibody was reacted with a 6 molar excess of linker-payload LP1 in 10% (v / v) DMSO at 25°C for 1 hour. Example 81 was purified from the unreacted linker-payload and DMSO using a PD-10 desalting column. The purified ADC was confirmed to be 100% monomeric by SEC and DAR 4.0 by LC-MS analysis.
[0466] Examples 81 to 121 were prepared using linker-payloads LP1, LP2, and LP6 to LP46 in the same manner as above and are shown in Table 4. In addition, ADCs with DAR 1.0 to 7.8 could be obtained by adjusting the TCEP equivalent number by 2 to 32 molars.
[0467] Example DAR (LP#) Example DAR (LP#) 814.0 (LP1) 1023.7 (LP27) 823.8 (LP2) 1034.1 (LP28) 837.8 (LP2) 1043.7 (LP29) 848.0 (LP6) 1053.7 (LP30) 853.6 (LP9) 1064.2 (LP31) 863.8 (LP10) 1073.9 (LP32) 872.0 (LP10) 1084.3 (LP33) 883.9 (LP11) 1094.0 (LP34) 892.5 (LP12) 1103.8 (LP35) 903.4 (LP13) 1114.1 (LP36) 913.5 (LP14) 1123.8 (LP37)923.9 (LP17)1133.8 (LP38)934.2 (LP18)1143.3 (LP39)944.2 (LP19)1153.4 (LP40)954.1 (LP20)1164.6 (LP41)961.0 (LP21)1174.0 (LP42)973.2 (LP22)1183.4 (LP43)983.9 (LP23)1193.7 (LP44)994.1 (LP24)1203.4 (LP45)1003.7 (LP25)1213.5 (LP46)1013.9 (LP26)
[0468]
[0469] Experimental Example 1: Evaluation of Cytotoxicity of Payload on Cancer Cells
[0470] In this experiment, we aimed to investigate the effects of compounds on the activity of blood cancer cell lines. For this purpose, we used HL-60, a promyelocytic cell line derived from an acute leukemia patient. HL-60 is a cell line with a TP53 mutation, which causes drug resistance in acute myeloid leukemia and is a mutation that occurs frequently in relapsed patients.
[0471] 20,000 cells per well were dispensed into 96-well plates (clear bottom white plates, Corning) mixed with 80 µl of medium. Each compound was diluted in dimethyl sulfoxide (4-fold dilution, a total of 10 concentrations) and 20 µl was added per well to achieve final concentrations ranging from 0.0015 nM to 100 nM. At this time, the final concentration of dimethyl sulfoxide treated in the cells was set to 0.1%.
[0472] Cells treated with the compound were cultured at 37°C for 72 hours under 5% carbon dioxide conditions. Cell lysis was induced in the cultured cells by treating them with CellTiter-Glo Reagent (Promega) at room temperature for 3 minutes. After stabilizing the luminescence signal for 5 minutes, the luminescence intensity was measured using an EnVisionTMLUX multimode microplate reader. The measured results were calculated as the percentage of cell growth compared to the control group. The concentration at which cell growth was inhibited by 50% (GI50) was calculated using the log(inhibitor) vs. normalized response analysis of the GraphPad Prism program.
[0473] The effect of neo-matrix degrading agents on cell death was observed as shown in Table 5.
[0474] Example HL-60 IC 50 (nM) Example HL-60 IC 50 (nM)11.55195.7522.062039.733.6214.1140.2922>10050.4231.3060.2524>10070.51250.6780.57261.1590.18275.39100. 44286.82114.06292.69121.82301.30131.24316.15142.31320.211527.85334.74165.03341.171727.1235>100181.53CC885 (ref)0.35
[0475]
[0476] Experimental Example 2: Evaluation of Cytotoxicity of Anti-CD33 Antibody Degrader Conjugate
[0477] The cell proliferation inhibitory activity of Examples 81 to 121 according to the present invention against blood cancer cells was measured, using HL-60, a promyelocytic cell line derived from an acute leukemia patient, and MV4-11, a cell line derived from an acute myeloid leukemia patient. MV4-11 is a cell line with a FLT3-ITD mutation, and the FLT3 mutation is the most commonly identified mutation in patients with acute myeloid leukemia and is associated with a poor prognosis.
[0478] The HL-60 cell line used in the experiment was cultured in RPMI 1640 medium containing 10% FBS and 1% penicillin / streptomycin. MV4-11 was cultured in IMDM medium containing 10% FBS and 1% penicillin / streptomycin.
[0479] HL-60 cell lines were seeded into 96-well plates (clear bottom white plate, Corning) at a density of 20,000 cells per well mixed with 80 µl of medium. Each ADC was diluted in the culture medium (5-fold dilution, total of 10 concentrations) and administered at a dose of 20 µl per well to achieve a final concentration of 0.0003 nM to 100 nM.
[0480] MV4-11 cell lines were seeded into 96-well plates (clear bottom white plates, Corning) at a rate of 20,000 cells per well mixed with 80 µl of medium. Each compound was diluted in dimethyl sulfoxide (4-fold dilution, a total of 10 concentrations) and administered at a dose of 20 µl per well to achieve final concentrations ranging from 0.0015 nM to 100 nM. At this time, the final concentration of dimethyl sulfoxide treated in the cells was set to 0.1%.
[0481] Cells treated with the compound were cultured at 37°C for 72 hours under 5% carbon dioxide conditions. Cell lysis was induced in the cultured cells by treating them with CellTiter-Glo Reagent (Promega) at room temperature for 3 minutes. After stabilizing the luminescence signal for 5 minutes, the luminescence intensity was measured using an EnVisionTMLUX multimode microplate reader.
[0482] The measured cytotoxicity results were calculated as the percentage of cell growth compared to the control group. The concentration (GI50) that inhibited cell growth by 50% was calculated in Tables 6 and 7, respectively, using the log(inhibitor) vs. normalized response analysis of the GraphPad Prism program.
[0483] Example HL-60 IC 50 (nM) Example HL-60 IC 50 (nM)810.0210216.5820.021030.02830.031043.7842501050.0685>1001064. 2860.0051073.9870.011084.388>1001094.0890.021103.8900.011114.1910 .0041123.8920.021133.8930.111143.3940.081153.4950.031164.69611.11174.0970.61180.005980.021190.00599>1001200.02100>1001210.021010.03
[0484] Compound MV4-11 C 50 (nM) Example 8 20.07 Mylotag (ref) 0.02 ORM-6151 (ref) 0.07
[0485]
[0486] Experimental Example 3: Evaluation of Neo-substrate Degradation Ability of Anti-CD33 Antibody Degrader Conjugate
[0487] The GSPT1 degradation ability of the anti-CD33-degrader conjugate according to the present invention (Example 82) was confirmed by comparison with ORM-6151. HL-60 cell lines, which are blood cancer cell lines expressing CD33, were used, and Western blot was used to quantify the amount of intracellular protein. The HL-60 cell lines used were cultured in RPMI 1640 medium containing 10% FBS and 1% penicillin / streptomycin. 300,000 HL-60 cell lines were dispensed per well into 6-well cell culture plates mixed with 2 ml of medium. Example 82 and ORM-6151 were diluted using RPMI 1640 medium and treated at 2 µl per well to achieve final concentrations of 30, 10, 3.3, 1.1, 0.4, and 0.1 nM.
[0488] Drug-treated cells were cultured at 37°C for 8 hours under 5% carbon dioxide conditions. The cultured cells were collected in a 1.7 ml microcentrifuge tube and centrifuged at 3,000 rpm for 3 minutes. Cell lysis and protein extraction were performed on the collected cells using RIPA buffer containing phosphatase inhibitors and protease inhibitors. During this process, the cells were maintained in a cold environment and vortexed every 10 minutes for a total of 30 minutes to facilitate cell lysis and protein extraction. Subsequently, the extracted proteins were centrifuged at 4°C, 13,000 rpm for 20 minutes, and their concentrations were calculated using the Bradford assay.
[0489] For the Bradford assay, 200 µl of 5x Bradford solution was added to each tube, followed by 2 µl of the extracted protein sample or BSA to be used as a concentration reference. Since the BSA used as the reference is 2 mg / ml, 8, 4, 2, and 1 µl were added to the tubes to establish concentration ranges of 16, 8, 4, and 2 µg / ml, respectively. Subsequently, the final volume of each tube was adjusted to 1000 µl using dH2O. After thoroughly mixing all tubes, 200 µl of each was transferred to a 96-well plate. Absorbance at a wavelength of 595 nm was measured using an Envision instrument. Based on the absorbance values from BSA, a baseline was plotted to calculate the protein concentration of each sample. Based on the calculated protein concentrations, SDS-PAGE samples at a concentration of 2 mg / ml were prepared by mixing RIPA buffer, 4x SDS sample buffer, and 2-Mercaptoethanol.
[0490] An 8% polyacrylamide gel was prepared for SDS-PAGE. The prepared gel was mounted in an electrophoresis tank and filled with 1x running buffer. After loading protein markers (5 µl) and samples (20 µl) into each well, electrophoresis was started at 80 V using a Power Supply Basic. Once the sample buffer entered the separating gel region, electrophoresis was performed at 120 V.
[0491] After the SDS-PAGE process was complete, the gel was separated, the stacking gel region was cut out, and placed on a PVDF membrane (pre-activated in 100% methanol for 3–5 minutes). Transfer buffer containing 10% methanol was filled into a tray, and the components were assembled from bottom to top in the following order: gray cassette, sponge, 3mm paper, PVDF membrane, SDS-PAGE gel, 3mm paper, sponge, and black cassette. The assembled cassette was placed in a transfer tank and filled with transfer buffer. Transfer was performed for 2 hours at 100 V using an HC power supply.
[0492] The transferred membrane was placed in a blocking buffer (a 5% skim milk powder solution prepared with 1x TBST buffer), and blocking was carried out for 1 hour at room temperature while shaking at 60–80 rpm. The GSPT1 antibody (Abclonal) and the β-actin antibody (Santa Cruz) were each diluted to 1:1,000 using the blocking buffer. The diluted GSPT1 antibody or β-actin antibody was added to the blocked membrane, and the reaction was carried out at 4°C for 16 hours.
[0493] The membrane was washed with 1x TBST buffer while shaking at 120–140 rpm at room temperature. The 1x TBST buffer was replaced every 10 minutes, and the washing was repeated a total of 3 times. The HRP-conjugated secondary antibody (Abcam) was diluted 1:5,000 using 1x TBST buffer. The diluted secondary antibody was added to the washed membrane, and the reaction was carried out for 1 hour while shaking at 40–60 rpm at room temperature. The membrane was washed with 1x TBST buffer while shaking at 120–140 rpm at room temperature. The 1x TBST buffer was replaced every 5 minutes, and the washing was repeated a total of 3 times. ECL solution (Cytiva) was mixed in a 1:1 ratio and sprayed evenly onto the washed membrane. After reacting at room temperature for 3 minutes, protein bands were observed using a G-Box instrument.
[0494] The intensity of each band was quantified using Image J software. The relative intensity was calculated by dividing each GSPT1 band intensity by the β-actin band intensity; then, with the GSPT1 relative intensity of the untreated sample set to 100, the relative intensity of GSPT1 at each drug concentration was calculated as a percentage. The calculated relative GSPT1 intensities were plotted as a graph of concentration (x-axis) versus GSPT1 relative intensity (y-axis) using GraphPad Prism software and are shown in Figure 1. The concentration at which GSPT1 is degraded by 50% (DC50) was calculated using the [inhibitor] vs. response analysis of GraphPad Prism software and is shown in Table 8.
[0495] Compound GSP1 DC 50 (nM) Example 820.05 ORM-6151 (ref) 0.18
[0496] Experimental Example 4: Evaluation of Anticancer Efficacy of Anti-CD33 Antibody Degrader in Mouse AML Model
[0497] The tumor-suppressing efficacy of the anti-CD33-degrader conjugate according to the present invention (Example 82) was evaluated in a mouse xenograft tumor model (human acute myeloid leukemia cells (AML)). BALB / c nude mice (6-8 weeks old, female) were used. After an acclimatization period, HL-60 and MV4-11 cells, respectively, were transplanted subcutaneously into the right flank of the mice. After confirming tumor formation, the mice were randomly separated into groups to ensure an average tumor size of approximately 100–200 mm³ per group, and drug administration was performed. During the course of administration, tumor size and individual body weight were measured at intervals of twice a week.
[0498] Figure 2 illustrates the in vivo activity of the anti-CD33-degrading drug conjugate against HL-60 (CD33+) tumors. The X-axis represents work after administration. The Y-axis represents the tumor volume (mm³) after administration of the vehicle, ORM-6151 (red line, 3 mg / kg), Example 82 (light green line, 1 mg / kg), and Example 82 (green line, 3 mg / kg).
[0499] Figure 3 illustrates the in vivo activity of the anti-CD33-novel degradation drug conjugate against MV4-11 (CD33+) tumors. The X-axis represents days after administration. The Y-axis represents the tumor volume (mm³) after administration of the vehicle, ORM-6151 (red line, 3 mg / kg), Example 82 (light green line, 1 mg / kg), and Example 82 (green line, 3 mg / kg).
[0500] As a result, in the experimental group that received a single intravenous administration of Example 82 (1-3 mg / kg), tumor regression due to drug administration was confirmed, and no change in body weight was observed.
[0501]
[0502] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
1. A compound selected from conjugates of urea derivative compounds represented by the following chemical formula 1 and stereoisomers thereof: [Chemical Formula 1] In the above chemical formula 1, a is an integer from 1 to 8; Ab is a CD33 antigen-specific binding antibody; L is a slicable linker; P is a payload having the characteristics of a neosubstrate decomposer represented by the following chemical formula 2; [Chemical Formula 2] In the above chemical formula 2, Above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 Each is independently hydrogen, an alkyl group, an aminoalkyl carbonyl group, an alkylaminoalkyl carbonyl group, a heterocycloalkyl carbonyl group, an aminoalkyl group, an alkylaminoalkyl group, a hydroxyalkyl carbonyl group, a cycloalkyl group, a halocycloalkyl group, a heterocycloalkyl group, a heterobicycloalkyl group, a cycloalkyl-alkyl group, a heterocycloalkyl-alkyl group, a hydroxycarbonylalkyl group, an alkylhydroxycarbonylalkyl group, an aminecarbonylalkyl group, or an alkylaminecarbonylalkyl group; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above-mentioned alkyl group, cycloalkyl group, and heterocycloalkyl group are substituted or unsubstituted with one or more selected from the group consisting of halogens and alkyls; Above A 2 is an alkyl group, an alkoxyalkyl group, an alkylaminocarbonylalkyl group, an alkylcarbonylaminoalkyl group, a carbonylalkyl group, an alkylaminoalkyl-alkyl group, an alcohol-alkoxyalkyl group, an alkylalkoxy-alkoxy group, or an alkylaminoalkyloxyalkyl group; Above A 2 The above alkyl group and alkoxy group are substituted or unsubstituted with one or more selected from the group of halogens and alkyls; The above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, an alkyl group, a hydroxyl group, an alkoxy group, an amine group, an alkylamine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; The above R 3 is hydrogen or an alkyl group; The above X is NH, C(=O), O, or CF2; The above Y is O, S and NH.
2. In Paragraph 1, The above-mentioned cleavable linker is a compound selected from a conjugate of a urea derivative compound and a stereoisomer thereof, characterized by having the structure of the following chemical formula 3, 4, or 5. [Chemical Formula 3] [Chemical Formula 4] [Chemical Formula 5] In the above chemical formulas 3, 4, and 5, represents the binding site with Ab; represents the binding site with the neo-substrate decomposer; W is -C(=O)-, -C(=O)NR'-, -NR'-, or -N(C=O)R', where R' is hydrogen, C 1-4 Alkylamino, -(CH2)nO(CH2)nNH 2, -NH(CH2)2OC(O)NHSO2NH(CH2)2-, -NH(CH2)2OC(O)NHSO2NH(CH2)O(CH2)n- and; n is an integer from 1 to 10, and; Z 1 , Z 2 , Z 3 and Z 4 are either independently non-existent or are naturally occurring amino acid residues in the L- or D-set, and only Z 1 , Z 2 , Z 3 and Z 4 At least two of them are amino acid residues; R 14 is non-existent, or is a C1~C3 alkoxy or -Ar-CH2OH-, and D is -(maleimide-N)- that binds to Ab.
3. In Paragraph 2, The above Z 1 , Z 2 , Z 3 and Z 4 is not present independently or is selected from the group consisting of L-valine, D-valine, L-citrulline, D-citrulline, L-alanine, D-alanine, L-glutamine, L-glutamic acid, D-glutamic acid, D-glutamine, L-aspartic acid, D-aspartic acid, L-asparagine, D-asparagine, L-phenylalanine, D-phenylalanine, L-lysine, D-lysine, and glycine; provided, however, that Z 1 , Z 2 , Z 3 and Z 4 A compound selected from a conjugate of a urea derivative compound and a stereoisomer thereof, characterized in that at least two of the groups are amino acid residues.
4. In Paragraph 3, A compound selected from a conjugate of a urea derivative compound and a stereoisomer thereof, characterized in that the above chemical formula 4 has the structure of the following chemical formula 6. [Chemical Formula 6] In the above chemical formula 6, R 14 is non-existent, or is a C1~C3 alkoxy or -Ar-CH2OH-, and D is -(maleimide-N)- that binds to Ab.
5. In Paragraph 4, The above D is a compound selected from conjugates of urea derivative compounds and stereoisomers thereof, characterized by having the structure of the following chemical formula 7 or 8. [Chemical Formula 7] [Chemical Formula 8] In the above chemical formulas 7 and 8, m is an integer from 1 to 4; represents the binding site with Ab; * indicates a binding site with W or an amino group.
6. In Chemical Formula 3 of Paragraph 2, The above W is a compound selected from conjugates of urea derivative compounds and stereoisomers thereof, characterized by having the structure of the following chemical formula 9 or 10. [Chemical Formula 9] [Chemical Formula 10] In the above chemical formulas 9 and 10 * indicates the connection point with the above D; The above R15 is bonded to a phenyl group, and R 15 is -NH- or -(OCH2CH2)nNH- and; n is an integer from 2 to 6.
7. In Chemical Formula 4 of Paragraph 2, The above R 14 A compound selected from conjugates of urea derivative compounds and stereoisomers thereof, characterized by having the structure of the following chemical formula 11 or 12. [Chemical Formula 11] [Chemical Formula 12] In the above chemical formulas 11 and 12, represents the binding site with the amino group; * indicates the connection point with P.
8. In Paragraph 1, Above A 1 is R 7 -(R 8 )NO-, R 9 -O-(R 10 )N-, R 11 -(R 12 )N-(R 13 )N- and; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently hydrogen, (C1-C5 alkyl) group, H2N-(C1-C5 alkyl)-C(=O)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-C(=O)-, (C3-C8 heterocycloalkyl)-C(=O)-, H2N-(C1-C5 alkyl)-, (C1-C5 alkyl)HN-(C1-C5 alkyl)-, HO-(C1-C5 alkyl)-C(=O)-, (C3-C8 cycloalkyl) group, (C3-C8 heterocycloalkyl) group, (C7-C 11 Heterobicycloalkyl) group, (C3-C8 cycloalkyl)-(C1-C5 alkyl)-, (C3-C8 heterocycloalkyl)-(C1-C5 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)- or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)- and; The above R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 The above (C1-C5 alkyl) group, (C3-C8 cycloalkyl) group and (C3-C8 heterocycloalkyl) group are substituted or unsubstituted with one or more selected from the group consisting of halogens and C1-C5 alkyls; Above A 2 is -(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)HN-C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-C(=O)-NH(C1-C5alkyl)-, -C(=O)-(C1-C5alkyl)-, -(C1-C5alkyl)-N(C1-C5alkyl)-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O-(C1-C5alkyl)-, -(C1-C5alkyl)-O-(C1-C5alkyl)-O- or -(C1-C5alkyl)HN-(C1-C5alkyl)-O-(C1-C5alkyl)- and; Above A 2 The above (C1-C5 alkyl) and (C1-C5 alkyl)-O are substituted or unsubstituted with one or more types selected from the group consisting of halogens and (C1-C5 alkyl); The above R 1 , R 2 , R 4 and R 5 Each is independently hydrogen, a halogen group, a (C1-C5 alkyl) group, a hydroxyl group, an alkoxy group, an amine group, a (C1-C5 alkyl)amine group, a nitrile group, a difluoromethyl group, or a trifluoromethyl group; The above R 3 is hydrogen or a (C1-C5 alkyl) group; The above X is NH, C(=O), O, or CF2; A compound selected from conjugates of urea derivative compounds and stereoisomers thereof, characterized in that the above Y is O, S, or NH.
9. In Paragraph 1, The above chemical formula 2 is the following chemical formula 2a or 2b; [Chemical Formula 2a] [Chemical Formula 2b] In the above chemical formulas 2a and 2b The above R 6 , R 7 , R 8 , and R 9 Each is independently hydrogen, (C1-C3 alkyl) group, H2N-(C1-C3 alkyl)-C(=O)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-C(=O)-, (C3-C6 heterocycloalkyl)-C(=O)-, H2N-(C1-C3 alkyl)-, (C1-C3 alkyl)HN-(C1-C3 alkyl)-, HO-(C1-C3 alkyl)-C(=O)-, (C3-C6 cycloalkyl) group, (C3-C6 heterocycloalkyl) group, (C7-C9 heterobicycloalkyl) group, (C3-C6 cycloalkyl)-(C1-C3 alkyl)-, (C3-C6 heterocycloalkyl)-(C1-C3 alkyl)-, HO-C(=O)-(C1-C5 alkyl)-, A compound selected from a conjugate of a urea derivative compound and its stereoisomers, characterized as being (C1-C5 alkyl)-OC(=O)-(C1-C5 alkyl)-, H2N-C(=O)-(C1-C5 alkyl)-, or (C1-C5 alkyl)HN-C(=O)-(C1-C5 alkyl)-.
10. In Paragraph 9, A compound selected from a conjugate of a urea derivative compound and a stereoisomer thereof, characterized in that the (C1-C3 alkyl) group, the (C3-C6 cycloalkyl) group, or the (C3-C6 heterocycloalkyl) group is substituted or unsubstituted with one or more types selected from the group consisting of F, Cl, and (C1-C3 alkyl).
11. In Paragraph 1, Above A 2 A conjugate of a urea derivative compound and the stereochemical thereof, characterized in that is -(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)HN-C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-C(=O)-NH(C1-C3alkyl)-, -C(=O)-(C1-C3alkyl)-, -(C1-C3alkyl)-N(C1-C3alkyl)-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-(C1-C3alkyl)-, -(C1-C3alkyl)-O-(C1-C3alkyl)-O-, or -(C1-C3alkyl)HN-(C1-C3alkyl)-O-(C1-C3alkyl)-. A compound selected from isomers.
12. In Paragraph 11, A compound selected from a conjugate of a urea derivative compound and a stereoisomer thereof, characterized in that the (C1-C3alkyl) and (C1-C3alkyl)-O are substituted or unsubstituted with one or more compounds selected from the group consisting of F, Cl, and (C1-C3alkyl).
13. In Paragraph 1, The above R 1 , R 2 , R 4 and R 5 A compound selected from conjugates of urea derivative compounds and stereoisomers thereof, each characterized as being independently hydrogen, F, Cl, Br, (C1-C5 alkyl) group, hydroxyl group, alkoxy group, or trifluoromethyl group.
14. In Paragraph 1, The above R 3 A compound selected from conjugates of urea derivative compounds and stereoisomers thereof, characterized in that the silver is hydrogen, a methyl group, an ethyl group, a propyl group, or an isopropyl group.
15. In Paragraph 1, A compound selected from conjugates of urea derivative compounds and stereoisomers thereof, characterized in that X is NH, C(=O), or CF2.
16. In Paragraph 1, A compound selected from conjugates of urea derivative compounds characterized in that Y is O or S, pharmaceutically acceptable salts thereof, hydrates thereof, and stereoisomers thereof.
17. In Paragraph 1, The compound of Chemical Formula 2 above is a compound selected from a conjugate of a urea derivative compound and a stereoisomer thereof, which is any one of the compounds in the group consisting of the following compounds: 1-(3-chloro-4-(2-(2-((methyl I2-azanyl)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; 1-(4-(2-(2-axyloxyethoxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide; 1-(3-chloro-4-(2-((methylamino)oxy)ethyl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)thiourea; 1-(4-(1-(2-(aminooxy)ethoxy)-2-methylpropane-2-yl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; 1-(3-chloro-4-(2-(2-(methoxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; 1-(3-chloro-4-(1-(2-(methoxyamino)ethoxy)-2-methylpropane-2-yl)phenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; N-(2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)-2-hydroxy-N-methylacetamide; 2-(aminooxy)-N-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethyl)acetamide; 1-(4-(2-(aminooxy)ethyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; 2-amino-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenetoxy)acetamide; 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; 3-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)propanamide; 2-amino-N-(2-((2-((2-chloro-4-(3-((2-((2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenetoxy)amino)-2-oxoethyl)amino)-2-oxoethyl)acetamide 2-(aminooxy)-N-(2-((2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)amino)-2-oxoethyl)acetamide; 2-(aminooxy)-N-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropyl)acetamide; Ethyl 3-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)propaneoate; 3-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)propanoic acid; 2-(aminooxy)-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)acetamide; 1-(3-chloro-4-(2-(2-((ethylamino)oxy)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)methyl)urea hydrochloride; 1-(4-((aminooxy)methyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; 2-amino-N-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethyl)acetamide; 1-(4-(2-(2-(aminooxy)ethoxy)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; 1-(4-(2-(aminooxy)ethyl)-3-chlorophenyl)-3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)urea; 1-(3-chloro-4-(2-(2-(hydroxyamino)ethoxy)ethyl)phenyl)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)urea; 2-(aminooxy)-N-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)propyl)ureido)phenethyl)acetamide; N-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenetoxy)azetidine-3-carboxaamide; 2-(aminooxy)-N-(2-chloro-4-(3-((1R)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenethoxy)acetamide; 2-(aminooxy)-N-(2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenyl)-2-methylpropyl)acetamide; Ethyl 3-((2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)amino)propaneoate; 2-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)acetamide; 2-((2-(2-(2-chloro-4-(3-((1S)-1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)ethyl)ureido)phenyl)-2-methylpropoxy)ethoxy)amino)acetamide; 2-amino-N-(2-((2-((2-chloro-4-(3-((2-((2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenetoxy)amino)-2-oxoethyl)amino)-2-oxoethyl)acetamide hydrochloride; Ethyl 3-((2-(2-chloro-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)ureido)phenethoxy)ethoxy)amino)propaneoate.
